



Preoperative exercise interventions to optimize continence outcomes following radical prostatectomy

Sean F. Mungovan^{1,2,3}✉, Sigrid V. Carlsson^{4,5,6}, Gregory C. Gass^{2,7}, Petra L. Graham⁸, Jaspreet S. Sandhu⁴, Oguz Akin⁹, Peter T. Scardino⁴, James A. Eastham⁴ and Manish I. Patel^{10,11}

Abstract | Urinary incontinence is a common and predictable consequence among men with localized prostate cancer who have undergone radical prostatectomy. Despite advances in the surgical technique, urinary continence recovery time remains variable. A range of surgical and patient-related risk factors contributing to urinary incontinence after radical prostatectomy have been described, including age, BMI, membranous urethral length and urethral sphincter insufficiency. Physical activity interventions incorporating aerobic exercise, resistance training and pelvic floor muscle training programmes can positively influence the return to continence in men after radical prostatectomy. Traditional approaches to improving urinary continence after radical prostatectomy have typically focused on interventions delivered during the postoperative period (rehabilitation). However, the limited efficacy of these postoperative approaches has led to a shift from the traditional reactive model of care to more comprehensive interventions incorporating exercise-based programmes that begin in the preoperative period (prehabilitation) and continue after surgery. Comprehensive prehabilitation interventions include appropriately prescribed aerobic exercise, resistance training and specific pelvic floor muscle instruction and exercise training programmes. Transperineal ultrasonography is a non-invasive and validated method for the visualization of the action of the pelvic floor musculature, providing real-time visual biofeedback to the patient during specific pelvic floor muscle instruction and training. Importantly, the waiting time before surgery can be used for the delivery of comprehensive prehabilitation exercise-based interventions to increase patient preparedness in the lead-up to surgery and optimize continence and health-related quality-of-life outcomes following radical prostatectomy.

Prostate cancer is a common malignancy and, as the fifth most common cause of cancer deaths in men, is a global public health problem^{1,2}. GLOBOCAN 2020 estimates reported 1,414,259 new cases of prostate cancer globally in 2020, with a higher prevalence in developed countries¹. Despite geographical and ethnic variations in the incidence rate, prostate cancer is one of the most frequently diagnosed non-cutaneous cancers. The highest estimated incidence rates per 100,000 males have been reported in Australia and New Zealand, North America, Western and Northern Europe and the Caribbean². The incidence rate of prostate cancer has been reported to be on an upward trajectory in Eastern Europe², the Middle East³, North Africa⁴ and in Central and South America⁵.

Not all prostate cancer diagnoses are terminal. The indolent nature of the disease is widely recognized and

can be successfully managed and treated⁶. Accurate tumour grading remains the cornerstone for diagnosis, risk stratification and clinical management decisions. Classification methods that guide the clinical management of prostate cancer incorporate tumour grade, the tumour, node, metastasis stage and PSA level. Patients with prostate cancer can be stratified into low-risk, intermediate-risk and high-risk disease groups⁷. In developed countries, most men who receive a diagnosis of prostate cancer present with organ-confined and potentially curable disease^{7,8}.

The high incidence rate and need for effective treatment options has led to extensive efforts to improve the assessment and clinical management of patients with prostate cancer. Treatment options continue to evolve to support patient-centred models of care, which

✉e-mail: sean.mungovan@crinstitute.com.au
<https://doi.org/10.1038/s41585-021-00445-5>

Key points

- The oncological curative effectiveness of radical prostatectomy can be diminished by treatment-related adverse effects that include urinary incontinence, reduced physiological functional capacity and psychosocial well-being.
- The increasing survival of men following radical prostatectomy has resulted in the development of preoperative interventions that can improve the patients' preoperative and postoperative experience and optimize health-related quality-of-life outcomes.
- Preoperative exercise interventions comprising a combination of aerobic exercise, resistance training and specific pelvic floor muscle training programmes are designed to enhance the patients' physiological functional capacity and mitigate the treatment-related adverse effects of radical prostatectomy including urinary incontinence.
- Transperineal ultrasonography can provide a non-invasive and validated method to improve the quality and specificity of the delivery of pelvic floor muscle training interventions in men before and after they undergo radical prostatectomy.
- A structured and coordinated prehabilitation model of care can be initiated by the surgeon and delivered through their multidisciplinary team to extend the surgical care provided to patients and optimize preoperative and postoperative functional outcomes.

are based on informed and shared decision-making between the patient and their clinicians⁹. Prostate cancer encompasses a wide spectrum of disease, ranging from indolent to highly aggressive tumours. The range of treatment options available to successfully manage clinically localized prostate cancer has evolved because of the significant variation in the potential clinical course of the disease and a better understanding of the genetic and molecular profile of the disease^{10–12}. These treatment options include active surveillance and definitive curative interventions including surgical resection, radiotherapy including external-beam and interstitial radiation, energy ablative technologies and/or androgen deprivation therapy (ADT)¹³. Although each treatment option has a unique efficacy profile, including treatment-related risks, benefits and adverse effects, the lack of robust comparative effectiveness trials mean that, as yet, no single treatment option has emerged as the most appropriate for patients with prostate cancer. In a patient-centred model of care, achieving the optimal balance of potential benefits, risks and adverse effects for each treatment option

adds to the complexity of informed and shared clinical decision-making for patients with localized prostate cancer.

Low-risk localized prostate cancer, which includes most men with Gleason Grade Group 1 disease, can be carefully monitored and managed using active surveillance protocols, delaying the need for curative interventions until evidence of disease progression is seen. Active surveillance was developed to personalize the need for early intervention, potentially circumventing the risk of functional impairments and other negative consequences of definitive curative treatment options¹⁴. For men with prostate cancer who require definitive curative treatment, the management options for localized prostate cancer include radical prostatectomy, radiotherapy, focal therapy and/or ADT, low-dose-rate brachytherapy and focal therapy alone^{15,16}. Men who present with locally advanced prostate cancer typically receive ADT as the primary intervention in conjunction with radiotherapy or, in some instances, surgery¹⁷. Although metastatic prostate cancer disease is primarily treated with ADT, clinical trials have reported the benefit of including docetaxel chemotherapy^{18,19} or abiraterone acetate to improve survival^{20,21}. Evidence suggests that radiotherapy and radical prostatectomy reduces disease burden and the need for palliative treatment, even in patients with metastatic disease²².

Radical prostatectomy

The surgical technique of prostatectomy has changed considerably over time from simple prostatectomy, which removed only parts of the prostate, to removal of the entire prostate using radical prostatectomy²³ (FIG. 1). The radical approach to prostatectomy was first reported in 1905 by Hugh Hampton Young²⁴ and remains the mainstay of surgical curative treatment for men with localized prostate cancer. Randomized controlled trials (RCTs) have confirmed that radical prostatectomy improves prostate cancer survival and reduces the incidence of metastasis compared with observation^{25,26}. The growing number of men who survive prostate cancer has widened the focus of clinical management to improve the patients' preoperative and postoperative experience, reduce the impact and hasten the recovery of treatment-related adverse effects and improve health-related quality of life.

Radical prostatectomy is a substantial life event for the patient²⁷. The majority of men who undergo radical prostatectomy experience predictable functional impairments including urinary incontinence and erectile dysfunction, regardless of the surgical approach — open retropubic, perineal and minimally invasive laparoscopic or robotic-assisted surgery^{28,29}. The combined effect of urinary incontinence and erectile dysfunction have far-reaching personal and societal consequences; a decrease in quality of life and psychosocial well-being, an increase in the use of health-care resources and lost work productivity^{30,31}. For men undergoing radical prostatectomy, the optimal postoperative outcomes include oncological control, return of urinary continence, erectile function, physiological functional capacity, as well as improved quality of life^{27,31–34}. Understanding

Author addresses

- ¹Westmead Private Physiotherapy Services, Westmead Private Hospital, Westmead, New South Wales, Australia.
- ²The Clinical Research Institute, Westmead, New South Wales, Australia.
- ³Department of Professions, Faculty of Health, Arts and Design, Swinburne University of Technology, Hawthorn, Victoria, Australia.
- ⁴Urology Service at the Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- ⁵Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- ⁶Institute of Clinical Sciences, Department of Urology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
- ⁷Physical Therapy Program, University of Jamestown, Fargo, ND, USA.
- ⁸Department of Mathematics and Statistics, Macquarie University, Macquarie Park, New South Wales, Australia.
- ⁹Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- ¹⁰Specialty of Surgery, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
- ¹¹Department of Urology, Westmead Hospital, Westmead, New South Wales, Australia.

the importance of the neuromuscular, vascular and soft-tissue anatomical components of the lower urinary tract, in particular the urethral sphincter complex, has been integral to the development and modifications of the surgical technique^{35–37} and for the development of exercise-based therapies to improve continence outcomes following radical prostatectomy³⁸.

In this Review, we describe the state of the art and evidence base for the inclusion of preoperative exercise interventions to optimize functional outcomes, particularly urinary continence, after radical prostatectomy. We highlight the opportunities provided by the implementation of a prehabilitation model of care to increase patient preparedness in the lead-up to surgery to optimize continence and health-related quality-of-life outcomes following radical prostatectomy.

Urinary continence and incontinence

The functional male lower urinary tract system consists of the bladder, which acts as a reservoir, and the bladder neck, urethra and the urethral sphincter complex, which form the outlet (FIG. 2). Voluntary urination (micturition) is a fundamental human function that is dependent on the coordination of the collection, storage and the controlled periodic release of urine from the bladder. The change from a storage to a voiding function occurs under voluntary control, following either a strong sensation that bladder emptying is necessary or in anticipation that future emptying might be difficult or not possible³⁹. Voluntary urination is a highly integrated function, and relies on a complex hierarchy of peripheral and central nervous system regulation that coordinates the activity of the smooth and striated musculature of the bladder and urethra^{40,41}. The micturition cycle is defined according to two phases: the bladder functioning as a reservoir (storage phase) and the urine being expelled (voiding phase)³⁹.

The voiding phase of the micturition cycle occurs via a coordinated detrusor contraction in conjunction with the opening or release of the outlet. The relaxation of the bladder neck and urinary sphincter complex decreases urethral pressure and resistance to outflow^{39,42}. At the completion of bladder emptying, voiding ceases and the lower urinary tract system returns to the default collection and storage function⁴³. Urinary continence is maintained when the outlet or urethral pressure is greater than storage or bladder pressure. Conversely, when involuntary uncontrolled urinary flow occurs (urinary incontinence), bladder pressure has exceeded urethral pressure and voluntary control is diminished temporarily or lost entirely^{39,44–46}.

Urinary incontinence after radical prostatectomy

Following radical prostatectomy, men can experience urinary incontinence symptoms or 'leakage' in supine positions, while upright and during activities that involve effort and exertion such as coughing, standing up, lifting weighted objects and walking^{47–49}. Despite the prevalence of incontinence after radical prostatectomy, no consistent or universally accepted definition of postprostatectomy incontinence is available. No consensus has been reached either for the standardization

of data collection procedures to effectively quantify the degree or severity of postprostatectomy incontinence outcomes^{50,51}.


Postprostatectomy incontinence can be attributed to three types of incontinence: intrinsic urethral sphincter deficiency (stress urinary incontinence; SUI), detrusor overactivity and/or reduced bladder compliance (urge urinary incontinence), or a combination of stress and urge urinary incontinence (mixed urinary incontinence)^{52–54}. SUI (also known as exertional urinary incontinence) occurs during functional activities when an increase in intra-abdominal pressure is transferred into the pelvis, resulting in uncontrolled leakage of urine^{55,56}. The Prostate Testing for Cancer and Treatment (ProtecT) trial, a clinical RCT that compared active surveillance, prostatectomy and radiotherapy with ADT, reported that radical prostatectomy had the greatest negative effect on urinary continence outcomes; 46% of men who underwent radical prostatectomy reported using pads for urinary incontinence at 6 months after prostatectomy and approximately 17% were still using pads for urinary incontinence 6 years after surgery⁵⁷. This continued use of bulky absorbent pads or diapers is often associated with embarrassment, can lead to low self-esteem and depression and compromise intimate relationships⁵⁸. The fear of leaking urine, the continued use of absorbent pads and potential urine odours can cause men to avoid their previous physical, intimate and social activities⁵⁹. Persistent postprostatectomy incontinence can also have economic consequences; the cost of incontinence-related health-care services, pads, diapers, undergarments⁶⁰ and delays in the return to work^{32,61}. Consequently, the return to continence should be an important point of discussion between the patient and their clinicians before and after radical prostatectomy.

Pathophysiology and risk factors

The pathophysiology of incontinence in men following radical prostatectomy is not completely understood. Notably, the pathophysiology of urinary incontinence in men is less well understood than incontinence in women as it has not been investigated to the same extent.

Aetiology and pathophysiology

Typically, the recovery of continence following radical prostatectomy is one of progressive improvement, gradually resolving in the first year with further improvements in urinary continence occurring up to 2 years after surgery⁵⁴. Although the functional anatomy of the lower urinary tract system is well described^{37,62}, the aetiology and pathophysiology of urinary incontinence following radical prostatectomy are less well understood. However, the variability of recovery time to continence is well documented^{63,64}. The resulting variation in the recovery time to continence and the possibility of not regaining continence can be a potential barrier to patient consent for curative surgery for prostate cancer. Persistent postprostatectomy incontinence following radical prostatectomy can also contribute to decisional regret for having consented to undergo radical prostatectomy⁶⁵.



◀ Fig. 1 | **A timeline of surgery for prostate cancer.** The surgical technique for performing radical prostatectomy has evolved over time, from total prostatectomy in the late nineteenth century to the robot-assisted procedure in the 2000s. The development of exercise-based interventions and pelvic floor muscle exercise programmes to manage postprostatectomy incontinence has been more recent, with the development of preoperative models of care and the application of transperineal ultrasonography for pelvic floor muscle training programmes^{238–258}. AUA, American Urological Association; PFME, pelvic floor muscle exercise; RP, radical prostatectomy; SUFU, Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction; TPUS, transperineal ultrasonography.

The membranous urethral length (MUL) — the distance from the prostatic apex to the point of entry of the membranous urethra at the penile bulb (FIG. 3) — and the preoperative and postoperative urethral sphincter function are important factors contributing to postprostatectomy incontinence^{63,66–76}. The MUL ranges from 5 mm to 34 mm (REF.⁷¹), contains smooth muscle fibres and is surrounded along its entire length by the striated urethral sphincter musculature (also known as the rhabdosphincter)^{62,77,78}. The combined and coordinated functionality of the smooth and striated muscle fibres has an important role in maintaining and increasing urethral closure function by increasing urethral pressure^{78,79}. A longer preoperative MUL is significantly associated with the return to continence after radical prostatectomy. Each extra millimetre of MUL confers a stepwise increase in the return of continence (HR 1.05, 95% CI 1.02–1.08, $P < 0.001$)⁷¹.

Urethral sphincter insufficiency (inadequate urethral sphincter function) can lead to a reduction in urethral pressure and functional urethral sphincter closure. Factors that affect urethral sphincter insufficiency include a short MUL⁷², direct surgical trauma to the sphincteric muscular structures surrounding the MUL during prostate resection, a disruption to the sphincteric innervation and supporting connective tissue structures, and hypoperfusion^{63,80–82}. Urodynamic investigations in men before and after radical prostatectomy have highlighted the importance of urethral sphincter closure function on continence recovery time after radical prostatectomy^{68,72,74}. Impaired urethral sphincter closure and the associated reduction in the maximal urethral closure pressure before and after radical prostatectomy are associated with postprostatectomy incontinence^{72–76}. A progressive and partial recovery of urethral sphincter closure function has been reported after radical prostatectomy. Continent patients demonstrate a greater capacity to increase urethral pressure with voluntary pelvic floor muscle contractions compared with incontinent patients^{72,83,84}. Continent patients are able to increase their urethral pressure 2.6 times higher than incontinent men during a voluntary pelvic floor muscle contraction (147.5 cmH₂O versus 56.3 cmH₂O, $P = 0.04$)⁷². The activation and coordinated function of the pelvic floor musculature to generate urethral closure pressures contributes to functional urethral sphincter closure and has been identified as an important determinant of continence status following radical prostatectomy⁸⁵. Prostatectomy removes the smooth muscle within the prostatic urethra, contributing to a reduction in urethral pressure³⁷. A postoperative anastomotic stricture can result in a reduction in urethral pressure during

pelvic floor muscle contractions owing to an increase in urethral stiffness and a decrease in urethral elasticity⁶³.

Surgical risk factors

Risk factors contributing to the pathophysiology of postprostatectomy incontinence can be categorized as surgery-related and patient-related. An understanding of these factors is important for risk stratification for postprostatectomy incontinence and surgical planning as well as preoperative and postoperative patient counselling. For example, understanding the surgical and patient-related risk factors can assist clinicians in explaining to patients the variability in continence recovery time that occurs between patients and if incontinence symptoms persist for an extended period of time. Preoperative and postoperative strategies to reduce postprostatectomy incontinence can be prioritized to meet the risk profile of each patient.

Regardless of the surgical approach to removing the prostate, changes will occur in the position and function of the remaining lower urinary tract anatomical structures including the bladder, membranous urethra, and the urinary sphincter complex. The urethrovesical junction is typically displaced inferiorly and the proximal membranous urethral stump is displaced within the pelvis to enable the formation of the urethrovesicular anastomosis^{86–88}. The preservation of the MUL, maintaining the functional integrity of the pelvic floor musculature and the supporting urethral structures, is important in determining postoperative functional outcomes⁸⁹. In 1905, Ballenger noted the critical relationship between the integrity of the membranous urethra and the risk of urinary incontinence, commenting “avoid laceration of membranous urethra, as incontinence of urine will follow”⁹⁰. Knowledge of the preoperative MUL alone or when incorporated into a nomogram can lead to effective preoperative patient counselling, to providing realistic expectations for the return to continence, and to help identify patients at increased risk of urinary incontinence⁹¹.

Surgical damage to the neuromuscular components of the membranous urethra, including the urethral sphincter complex can occur during prostatectomy, resulting in sphincter insufficiency⁶³. Damage to, or removal of, the neurovascular bundles can affect continence recovery^{63,92}, and the substantial variability in the return to continence. To minimize surgery-related neuromuscular effects of radical prostatectomy, modifications to the surgical technique have included Retzius-sparing surgery, endopelvic fascia preservation, and the use of different sutures and stitches. However, these modifications to the surgical technique have not been universally accepted owing to the inability to identify, preoperatively, patients at high risk of urinary incontinence, concerns about overtreatment and a lack of empirical data demonstrating effectiveness of the modifications^{93–95}.

Whether posterior musculofascial reconstruction (the Rocco stitch) can improve continence is controversial and requires further investigation in prospective, robust, large-scale RCTs. A systematic review and meta-analysis reported that posterior musculofascial

reconstruction significantly improved return to continence at 3–7 days, 30 days and 90 days after catheter removal: relative risk (RR) 1.90, 95% CI 1.25–2.90, $P = 0.003$ (9 studies, of which 1 was an RCT), RR 1.77, 95% CI 1.43–2.20, $P < 0.001$ (16 studies, of which 2 were RCTs) and RR 1.32, 95% CI 1.10–1.59, $P = 0.003$ (16 studies, of which 2 were RCTs), respectively). A smaller, but still statistically significant, advantage was observed at 6 months (RR 1.13, 95% CI 1.02–1.26, $P = 0.025$ (13 studies, of which 1 was an RCT))⁹⁶. The surgical techniques have evolved, whereby some surgeons have proposed other operative technical steps around the urinary sphincter complex to improve continence, including a suburethral stitch, dissection methods to maximize urethral length and Retzius-sparing surgery²³. Other surgeons advocate for a ‘minimalist’ approach to avoid additional damage to the striated urethral sphincter and/or its innervation⁸¹. Surgeon skill and experience are important determinants of the oncological (biochemical recurrence; BCR) and functional (urinary and erectile function) outcomes after radical prostatectomy. Surgeons who have performed an increased number of radical prostatectomies report improved oncological and functional patient outcomes^{97–103}.

Patient risk factors

Prognostic patient risk factors affect the severity, duration and the recovery of postprostatectomy incontinence^{63,91}. Many of these risk factors are non-modifiable, for example, patient age^{63,91,104}, the preoperative MUL⁷¹ and prostate size⁶³. The duration of the continence recovery and the risk of persistent urinary incontinence symptoms

increases with advancing age^{63,91}, a shorter MUL⁷¹ and greater prostate size^{63,66}. Advancing age and MUL have consistently been reported as predictors of poor continence outcomes and are associated with a decrease in the volume and density of striated muscle cells in the striated urethral sphincter^{63,104}. Patients who present with non-modifiable risk factors should consider additional targeted preoperative interventions including a focus on training the striated urethral sphincter to mitigate the additional risk¹⁰⁵. An understanding of non-modifiable risk factors can be important during preoperative discussions with patients when setting expectations about the time course of the recovery of continence and the possibility of prolonged postprostatectomy incontinence. Understanding these non-modifiable risk factors can also be motivational for patients to undertake comprehensive preoperative exercise interventions to improve the continence recovery time.

Modifiable patient risk factors for the return to continence include BMI, metabolic comorbidities such as diabetes, pre-existing lower urinary tract symptoms and a lower preoperative maximal closure pressure^{54,63,68,70,83,105}. BMI is a known risk factor for prostate cancer progression and postprostatectomy incontinence^{91,106}. A study of 2,849 patients from a high-volume single centre reported that the risk of incontinence at 6 and 12 months following prostatectomy increased with a shorter MUL, increasing age and BMI⁹¹. Exercise-based interventions include aerobic exercise, resistance training and targeted pelvic floor muscle training (PFMT) programmes and are introduced during the preoperative period to modify the risk factors to improve continence outcomes.

Rehabilitation and prehabilitation

The excellent long-term oncological outcomes associated with radical prostatectomy have shifted the focus from oncological control to refinement of the surgical technique and delivering interventions to optimize postoperative functional outcomes. A return to continence is a major priority for the patient, the surgeon and their multidisciplinary health-care team. Traditional approaches to improving postprostatectomy continence outcomes have focused on technical advances in the surgical technique and postoperative PFMT interventions or rehabilitation^{64,107}. For persistent postprostatectomy incontinence, where conservative treatments have not been effective, surgical placement of a circumferential artificial urinary sphincter or a non-circumferential retourethral transobturator sling device is used for the management of patients with persistent postprostatectomy incontinence symptoms¹⁰⁸. The traditional model of care for the management of postprostatectomy incontinence has focused on treatment interventions commencing in the postoperative period. Such an approach to clinical management disregards the opportunities offered by those same treatment interventions delivered in the preoperative period and known as ‘prehabilitation’.

Prehabilitation

In prostate cancer care, prehabilitation is a model of care that commences preoperatively. The aim of preoperative interventions is to improve the postoperative





Fig. 2 | A sagittal view of the anatomy of the male lower urinary tract system. The action of the puborectalis, striated urethral sphincter and bulbocavernosus muscles during voluntary pelvic floor muscle contraction is indicated by the arrows. Reprinted with permission from REF.¹⁵⁷, Elsevier.

functional capacity, the trajectory of the recovery from urinary continence, and patient well-being and quality of life^{38,109–111}. The duration of a patient-centred prehabilitation programme is determined partly by the length of each patient's surgical wait time, which is defined as the time from prostate cancer diagnosis to the date of surgery. Surgical wait time can typically range from less than 2 weeks to several months, depending upon the patient, surgeon, hospital, health-care system, health insurance status and societal factors including access to health care and transportation^{112–117}. Countries operating under publicly funded health-care systems, such as Sweden, the UK, Canada and Australia, have surgical wait times for radical prostatectomy^{112–114}. For example, the mean surgical wait time for radical prostatectomy in Sweden in 2017 was 38 days, with the mean total time from the initial referral to the urologist by the primary care practitioner to the date of surgery 137 days¹¹⁴. The 2017–2018 mean wait time from prostate cancer diagnosis to surgery in public hospitals in Australia was 47 days¹¹⁵.

In countries where private health-care systems operate, the surgical wait time at private hospitals can be determined by the surgeon and/or institutional availability and insurance clearance requirements. Additional tests, examinations and prostate cancer staging investigations, such as CT imaging, bone scans and PSMA-PET scans can increase the surgical wait time¹¹⁸. The current clinical management of the COVID-19 pandemic has affected health-care resource allocation, resulting in an increase in wait time for curative oncological procedures, for example, radical prostatectomy^{119,120}. The involvement of multidisciplinary health-care teams, in which the patient plan of management includes a comprehensive informed and shared decision-making protocol, might result in patients taking additional time to seek a second opinion from other specialists, including urologists, radiation oncologists or medical oncologists. The surgical wait time, once viewed as an impediment, now presents a unique opportunity for implementation of prehabilitation programmes to prepare patients physically and psychologically to mitigate the predictable consequences of radical prostatectomy. Shorter surgical wait times can limit the prehabilitation opportunity¹²¹.

During the surgical wait time, patients can experience anxiety, uncertainty, depression and fear of disease progression^{122,123}. The effects of surgical wait times on oncological outcomes and survival rates following radical prostatectomy have been investigated with conflicting results. Some studies have supported^{124–126} and others have refuted^{117,127–133} the increased risk of poorer oncological outcomes from extended surgical wait times. At present, no consensus or evidence-based guidelines have been established to define a safe maximum surgical wait time for the management of clinically localized prostate cancer. Clinically, the recommended maximum surgical wait time for men with high-grade disease is shorter than that for men with low-risk disease^{134,135}. Abern and colleagues reported a significantly increased risk of positive surgical margins and BCR after radical prostatectomy among men with intermediate-risk prostate cancer when surgery was delayed by >9 months

a T2-weighted midsagittal magnetic resonance imaging



b Transperineal ultrasound imaging in supine




Fig. 3 | Imaging measurement of membranous urethral length. These images show a T2-weighted mid-sagittal magnetic resonance image (part **a**) and a 2D transperineal ultrasound image of the male lower urinary tract system (part **b**). The apex of the prostate, the penile bulb and the membranous urethra are identified. The length of the membranous urethra is measured from the apex of the prostate to the point of entry at the penile bulb. MUL, membranous urethral length. Adapted with permission from REF.¹⁹², Taylor & Francis.

(odds ratio (OR) 4.08, 95% CI 1.52–10.91, $P = 0.005$ for positive margins and HR 2.19, 95% CI 1.24–3.87, $P = 0.007$ for BCR)¹²⁷. However, Vickers and colleagues report data from 3,149 consecutive patients undergoing radical prostatectomy and found no significant evidence that delaying the time between diagnosis and surgery increased the risk of BCR at 3, 5, 8 and 10 years (ORs per month delay were all close to 1, all P values > 0.2). For patients undergoing surgery <6 months after diagnosis, the OR for each additional month of delay was 1.07 (95% CI 0.94–1.21, $P = 0.3$) for 5-year BCR and 1.02 (95% CI 0.85–1.22, $P = 0.9$) for 10-year BCR. Taken together, these results suggest that the effect of surgical wait time on oncological outcomes is moderate at 6–12 months; however, the 95% confidence intervals (CIs) were wide and included the possibility that minor

delays in surgery might have a large impact on the risk of BCR¹³⁰. These data are supported by further studies. Redaniel and colleagues found no significant difference in 5-year and 10-year survival in men who underwent radical prostatectomy at 0–3 months after their diagnosis compared with men who underwent radical prostatectomy 4–6 months after diagnosis (5-year relative survival (a measure of survival, having accounted for underlying mortality rates) 1.04, 95% CI 1.03–1.04 in those men who underwent surgery at 0–3 months after diagnosis, versus 1.05, 95% CI 1.04–1.05 among those who had surgery at 4–6 months after diagnosis; 10-year relative survival 1.07, 95% CI 1.05–1.09 versus 1.08, 95% CI 1.06–1.10, *P* not reported)¹³². Boorjian and colleagues used multivariate modelling to adjust for year of biopsy, PSA before biopsy, clinical stage and biopsy Gleason score, and reported that surgical wait time before prostatectomy within 1 year of diagnosis (either as continuous variable or categorized at 3 months) was not associated with a significantly increased risk of BCR (HR 0.98, 95% CI 0.95–1.02, *P* = 0.252 for the continuous variable and HR 1.01, 95% CI 0.81–1.26, *P* = 0.939 for the categorical variable)¹³¹. Finally, Lee and colleagues reported no significant correlation between the biopsy-to-surgery time that ranged from 14 to 378 days and postoperative oncological outcomes (multivariate logistic regression adjusting for Gleason score, PSA at biopsy and age, OR 0.999, 95% CI 0.991–1.006, *P* = 0.715 for positive surgical margins and OR 0.994, 95% CI 0.971–1.017, *P* = 0.62 for BCR)¹¹⁷.

A structured, targeted and coordinated prehabilitation model of care led by the surgeon and delivered through their multidisciplinary health-care team can extend the surgical care provided to the patient. Surgical wait time should now be considered an important component of the patients' surgical care pathway, during which time each patient actively participates in a structured and defined programme of prehabilitation. This prehabilitation period is aimed at reducing the patient's risk of postoperative functional impairments before their surgery and increasing their physical functional capacity, including aerobic exercise capacity, muscle strength and psychosocial well-being. Such prehabilitation programmes that incorporate exercise-based interventions represent a shift from the traditional 'reactive' postoperative rehabilitation model for managing the predictable consequences of radical prostatectomy to a 'proactive' model that provides 'patients with the opportunity to be an active participant in the clinical management of his prostate cancer. Prehabilitation programmes can be individually designed and implemented to address and manage each patient's risk factors and to improve the postoperative physical and psychosocial outcomes.

Multidimensional prehabilitation programmes can incorporate structured exercise, psychological, nutritional and behavioural interventions. Exercise-based prehabilitation programmes are based on the principles that a structured and sustained exercise-training stimulus during the surgical wait time can lead to positive physiological adaptations and psychological benefits, with significant positive consequences for the patient preoperatively and postoperatively^{38,109–111}.

Preoperative exercise-based interventions

Prescribing an appropriate exercise stimulus for men before their radical prostatectomy surgery can result in beneficial adaptations at the individual muscle level and across the cardiovascular, respiratory, musculoskeletal, neurological, metabolic and endocrine body systems. In addition to these physiological adaptations are positive psychosocial benefits, including a decrease in anxiety, improving mood and quality of life and reduced sick leave^{109,136–138}. Physical exercise interventions to improve functional outcomes before and after radical prostatectomy are categorized as aerobic exercise, resistance training and specific PFMT programmes. Prescribed exercise interventions require regular and sustained patterns of exercise behaviours in the preoperative period that are maintained and transferred into the postoperative period. Despite the increasing prescription of exercise in the preoperative period, little consensus exists as to the optimal exercise dose–response relationship. For example, exercise recommendations vary regarding the numbers of weeks prior to prostatectomy to commence the pelvic floor muscle exercise (PFME) programme, the number of sessions per day, the number of repetitions per session to optimize postsurgical outcomes after radical prostatectomy¹³⁹.

Aerobic exercise and resistance training

Radical prostatectomy results in a decreased physiological functional capacity²⁸. Contributing to the decrease in physiological functional capacity are the effects of the surgery, anaesthesia, wound healing, generalized fatigue and subsequently reduced physical activity during the postoperative period^{28,140}. Surgeons typically recommend that patients stay 'physically active', but often do not offer any specific exercise prescription to do so. Aerobic exercise typically incorporates activities using large muscle groups, for example, walking, running and cycling. Aerobic exercise can be continuous or intermittent and undertaken over varying periods of time and with different levels of intensity. The dose of aerobic exercise includes the frequency (times per week), duration (the length of each session (mins)) and the length of the entire exercise programme (weeks). The intensity of the exercise prescribed is usually a percentage of a maximum physiological response; for example, the age-predicted maximum heart rate (calculated HR_{max}) or measured or predicted oxygen uptake, or as a rating of perceived exertion (effort) using the Borg Scale¹⁴¹. The American Cancer Society's Nutrition and Physical Activity Guidelines for Cancer Survivors recommend undertaking a minimum amount of 'moderately' intense aerobic exercise for a total of 150 min per week, in bouts of 10 min or more¹⁴² or when time is a barrier, patients undertake a minimum of 75 min of 'vigorously' high-intensity aerobic exercise per week with similar effect¹⁴². The American Cancer Society¹⁴², American College of Sports Medicine¹⁴³ and Physical Activity Guidelines Advisory Committee's physical activity guidelines have recommended aerobic exercise intensities for cancer survivors¹⁴⁴ (TABLE 1). Such recommendations are only general guidelines that can guide patient-centred programmes. Each exercise prescription

Table 1 | Recommended exercise intensity based on guidelines for cancer survivors

| Exercise category | HR _{max} (%) | Rate of perceived exertion (Borg Scale) | Recommended duration |
|-------------------------|-----------------------|---|----------------------|
| Mild | <60 | ≤10 | NA |
| Moderate | 60–84 | 11–14 | 150 min per week |
| Vigorous/high-intensity | ≥85 | ≥15 | 75 min per week |

Recommendations based on the American Cancer Society¹⁴², American College of Sports Medicine¹⁴³ and Physical Activity Guidelines Advisory Committee¹⁴⁴. NA, not applicable; HR_{max}, age-predicted maximum heart rate, calculated as 220 – age (years).

should be tailored to each patient's medical history, physical capabilities and health status.

By contrast, resistance training involves repeated sets of movements against an external load or resistance¹⁴². In a systematic review and meta-analysis of 25 RCTs involving 819 participants, Borde and colleagues reported that resistance training programmes in healthy men 60–90 years of age resulted in a significant increase in upper and lower limb muscle strength compared with a control group of men who were not physically active (standardized mean difference between groups across studies SMD_{bs} 1.57, 95% CI 1.20–1.94, $P < 0.01$) indicative of a large effect size (Cohen's $d \geq 0.80$)¹⁴⁵. The benefits of resistance training programmes can extend beyond improvements in muscle strength and morphology, with improvements in functional mobility (walking endurance, gait speed, stair climbing), balance and falls prevention. Resistance training programmes of longer duration can result in greater increases in muscle strength. The resistance training programmes of 50–53 weeks typically have the greatest effect¹⁴⁵ (TABLE 2). Although the duration of preoperative resistance training programmes will be largely determined by the surgical wait time; a study of men aged 70–80 years reported a significant increase in maximum lower limb muscle strength after 4 weeks of resistance training (from a mean of 41.9 kg (standard error of the mean (s.e.m.) 6.3) to 57.3 kg (s.e.m. 7.4) in the intervention group, $P < 0.001$) compared with control and aerobic exercise groups¹⁴⁶. The resistance training exercise dose for this investigation included low-intensity resistance training for weeks 1 and 2: 50% of 1 repetition maximum (1RM), where 1RM is equal to the maximum weight that can be lifted for one repetition only, 3 sets of 8–10 repetitions and 3 sessions/week; followed by high-intensity resistance training for weeks 3 and 4: 70–80% of 1RM, 3 sets and 6–10 repetitions and 3 sessions/week¹⁴⁶. The recommended dose is consistent with that described by Borde and colleagues¹⁴⁵.

The benefits of a structured prehabilitation programme for the patient have been reported. An RCT that included 86 men undergoing radical prostatectomy reported that prehabilitation — comprising 60 min of home-based moderately intense exercise, 3 to 4 days per week, for approximately 6 weeks before surgery — significantly decreased participants' BMI and waist circumference (mean between-group difference 0.48 kg/m², 95% CI 0.16–0.79, $P = 0.003$, 1.38 cm, 95% CI 0.20–2.55, $P = 0.022$), improved the 6-min walk test distance (m) at 4 weeks (mean between-group difference 39 m, 95% CI 11–66, $P = 0.006$), and reduced anxiety (mean

between-group difference in Hospital Anxiety and Depression Scale score -1.59 , 95% CI -2.99 to -0.20 , $P = 0.025$) compared with controls. The controls received usual care that included information about PFMT, mobilization and time frames for the return to normal activities from a urology nurse over the phone and in a study manual. No adverse events were reported^{109,147}. Further support for prehabilitation programmes is from an observational study of men undergoing radical prostatectomy who were prescribed a supervised resistance and aerobic exercise programme twice a week, for 6 weeks before surgery. A significant increase in muscular strength (increased by 7.5% to 24.3%, $P < 0.05$) and a decrease in 400-m walk test time by 7.4% between baseline and presurgery (mean difference -17.2 s faster, 95% CI -30.3 , -4.1 , $P = 0.012$) were reported. These significant improvements in strength and 400-m walk test time were maintained postoperatively. Importantly, no adverse effects of the combined exercise programme were reported¹⁴⁸.

Pelvic floor muscle training

Exercising the pelvic floor musculature is the primary, non-invasive conservative intervention for the management of postprostatectomy incontinence¹⁰⁸. PFMT can be defined as 'any programme of repeated voluntary pelvic floor muscle contractions taught by a health-care professional'¹⁴⁹. The American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) both distinguish between PFMEs, which are self-guided programmes, and PFMT, which involves a health-practitioner-guided training programme specific to the pelvic floor musculature¹⁵⁰. PFMT for urinary incontinence in women is well-described. In 1948, Arnold Kegel first described pelvic floor exercises for women with SUI¹⁵¹. PFMT for female incontinence has evolved considerably since that time¹⁵². In 1975, Krauss and colleagues described perineal exercises with digital biofeedback to 're-educate' the sphincter in men who had undergone radical prostatectomy¹⁵³. However, the development and delivery of PFMT programmes for men undergoing radical prostatectomy is variable^{139,154}. The standard of care for men has traditionally included non-standardized verbal and written instructions to teach and encourage 'Kegel exercises' before surgery and then instructions for the patient to commence limited PFMT after their surgery¹³⁹. The Kegel exercise programme typically focuses on concentric contractions of the pelvic floor musculature whilst in stationary postures, such as sitting, and not necessarily during coordinated dynamic functional tasks, such as standing up, walking or lifting weighted objects, which typically provoke postprostatectomy incontinence symptoms. This ad hoc approach to the teaching and prescription of PFMEs can result in men not performing these exercises correctly and not achieving the expected pelvic floor muscle adaptations^{139,155,156}. Furthermore, the composition of the reported PFMT interventions is particularly heterogeneous. The duration of treatment sessions to teach pelvic floor muscle contractions can range from 15 to 90 min, the number of sessions provided can range

Table 2 | Recommendations for resistance training programmes in healthy older men¹⁴⁵

| Resistance training factors | Recommendation |
|--|--|
| Types of resistance training equipment that can be used | Resistance bands, free weights, weight machines and body weight exercise that incorporate large muscle groups |
| Type of muscle contraction | Concentric, eccentric and isometric |
| Training frequency (number of sessions per week) | A minimum of two non-consecutive sessions per week |
| Training intensity, percentage of 1RM ^a | High: $\geq 70\%$ 1RM; moderate: $< 50\text{--}70\%$ 1RM; low: $\leq 50\%$ 1RM 70–79% 1RM for optimal strength training effects |
| Number of repeated bouts (sets) per muscle group | Two to three sets per muscle group exercise, 60-s rest between each set |
| Number of repetitions ('reps') within each set of exercise | 7–9 reps per set, 4-s rest between each repetition |

^a1RM is equal to the maximum weight that can be lifted for one repetition only.

between 1 and 74 sessions and the quality of the training instructions can vary¹³⁹. As a result, the modest reported efficacy of postoperative PFMT programmes might be due to the ad hoc instructions and prescription of the exercise training intervention rather than the intervention itself^{156,157}. Despite the limited efficacy, postoperative training of the pelvic floor musculature continues to be the primary treatment approach to postprostatectomy incontinence^{53,150}.

The suggested mechanisms of action for PFMT to improve continence outcomes after prostatectomy are mediated through an improvement in activation, coordination, strength and endurance of the pelvic floor musculature¹⁵⁷. The reported hypertrophy of the striated muscles and an increase in strength, endurance and coordination of the pelvic floor musculature can amplify urethral pressure to reduce postprostatectomy incontinence symptoms^{157–159}. The efficacy of PFMEs and/or PFMT might depend on the pelvic floor muscle targeted and the exercise training stimulus applied to the targeted pelvic floor muscle¹⁵⁷. Continence recovery after radical prostatectomy is associated with an increase in striated pelvic floor muscle function^{85,160}. Men who regain continence after radical prostatectomy demonstrate a greater displacement of the mid-urethra (striated urethral sphincter), anorectal angle (puborectalis) and the penile bulb (bulbocavernosus) during voluntary pelvic floor muscle contractions and when coughing than men with postprostatectomy incontinence and men who have not undergone radical prostatectomy¹⁶⁰. When striated urethral sphincter function is reduced following prostatectomy, compensatory activation of the bulbocavernosus and puborectalis has been identified⁸⁵.

Evidence for rehabilitative PFMT. Prescribing PFMEs in the management of postprostatectomy incontinence remains part of the current standard of care after radical prostatectomy, as recommended in clinical practice guidelines¹⁶¹. The 2019 AUA/SUFU guideline for incontinence after prostatectomy recommends that clinicians offer PFMEs and/or PFMT in the 'immediate post-operative period'¹⁵⁰. RCTs have supported the notion

that PFMEs and/or PFMT started postoperatively to improve the time-to-continence compared with controls (in most studies, controls receive usual care; verbal and/or written instructions to start limited PFMEs postoperatively)^{150,156,162–165} (TABLE 3). However, a 2020 systematic review and meta-analysis that included 10 RCTs of PFMEs starting postoperatively found no significant difference in the risk of incontinence 3 months after surgery between men who had performed postoperative PFMEs and the control group (in most studies, usual care) (RR 0.90, 95% CI 0.79–1.02, $P=0.10$)¹⁵⁶. Similarly, other studies of PFMEs commencing after surgery have also reported no significant differences in long-term urinary continence outcome between men who received the postoperative PFMT intervention versus controls (in most studies, usual care)^{154,155,166,167}. A 2015 Cochrane review that included eight RCTs comprising a total of 2,736 patients found no significant difference in 12-month continence rates between men who undertook postoperative PFMEs and/or PFMT compared with control patients who did not (57% urinary incontinence at 12 months in the intervention groups versus 62% in the control group; RR 0.85, 95% CI 0.60–1.22)¹⁶⁶.

The prescribed intensity of the PFME or PFMT programme might partially explain its efficacy. A meta-analysis showed that postoperative PFME training comprising at least 3 sets of 10 repetitions per set daily improved urinary incontinence in both the short term (RR 2.16, 95% CI 1.79–2.60 at 3 months, $P<0.001$, 4 studies) and the long term (RR 1.23, 95% CI 1.04–1.47 at 12 months, $P=0.019$) when compared with controls¹⁶². The long-term data included 3 studies, one of which used an intensive programme that started at the time of catheter removal and continued while incontinence persisted¹⁶⁸.

Evidence for prehabilitative PFMT. PFMT can be effective at restoring continence after radical prostatectomy if men are taught to correctly activate and effectively train the pelvic floor musculature starting before surgery (prehabilitation), rather than after surgery (rehabilitation). The biological rationale for starting PFMT before surgery includes an increase in the neuromuscular reserve, that includes increased muscle mass, strength and endurance of the striated muscles of the pelvic floor to compensate for the loss of smooth and striated muscles during radical prostatectomy¹⁵⁷. In addition, the preoperative PFMT prepares patients with the motor skills to begin exercise immediately after removal of the urinary catheter^{157,169}.

Although the 2019 AUA/SUFU guideline states that the "effectiveness of PFME/PFMT has not been definitively shown in the preoperative period", those same guidelines recommend that patients can be offered prehabilitative PFME and/or PFMT because the "potential benefits outweigh any potential risks"¹⁵⁰. The guidelines suggest starting exercises 3–4 weeks preoperatively to enable neuromuscular adaptation to increase the neuromuscular reserve.

The evidence supporting the commencement of PFMEs preoperatively is growing. A number of studies have compared preoperative PFMT with control groups,

Table 3 | Trials of prehabilitative PFME programmes versus standard of care

| Refs | Study design | Intervention | Control | Time of postoperative evaluation | Outcomes | Limitations | Authors' conclusions |
|---|--------------------|---|---|----------------------------------|---|--|---|
| Yoshida et al. (2019) ¹⁸⁸ | Prospective cohort | PFMT with TPUS biofeedback for <4 weeks preoperatively (n=36) | Verbal instructions after RP (n=80) | 1, 3, 6 months | Time to continence recovery: intervention: 76 ± 100 days; control: 122 ± 132 days (P=0.037); continence defined as number of days requiring a small pad (20 g) per day by self-report | Small study Not an RCT; risk for selection bias Imbalanced study groups | Preoperative TPUS-PFMT was associated with early recovery of urinary continence after RP |
| Milios et al. (2019) ²²⁸ | RCT | PFMT (6 sets/day) with transabdominal ultrasound biofeedback 5 weeks preoperatively and for 12 weeks postoperatively (n=50) | Preoperative PFMT (3 sets/day) 5 weeks preoperatively and for 12 weeks postoperatively (n=47) | 2, 6, 12 weeks | Continent at 6 weeks: intervention: 32%; control: 11% (P<0.05); continent at 12 weeks: intervention: 74%; control: 43% (P<0.05); continence defined using 24-h pad weight | Small study Control group also received preoperative care, but a less intense programme | An intensive PFMT programme commenced before RP improved postoperative PFM function and urinary continence |
| Aydin Sayilan and Ozbas (2018) ²²⁹ | RCT | Supervised and unsupervised 6-month Kegel exercise programme with transabdominal ultrasound biofeedback starting 1 week preoperatively (n=30) | No PFME (only breathing exercises) (n=30) | 1, 3, 6 months | ICIQ-UI at 3 months, mean (s.d.), intervention: 9.0 (3.6); control: 14.3 (3.3) (P<0.01); ICIQ-UI at 6 months: intervention: 6.2 (2.9); control: 14.6 (3.0) (P<0.01); no pads Pad use at 1/3/6 months: intervention: 20%/23.3%/50%; control: 6.7%/3.3%/3.3% Primary definition of continence: ICIQ-UI=0; secondary definition= pad use | Small study No exercises at all in the control group | PFMEs are suitable for patients experiencing incontinence after RP |
| Dijkstra-Eshuis et al. (2015) ²³⁰ | RCT | PFMT with biofeedback for a minimum of 4 weeks preoperatively (n=65) | Standard of care (n=56) | 6 weeks, 3, 6, 9,12 months | 1 year: intervention: 65.5% continent; control: 80%; continence defined as 0 g on 24-h pad weight test (P>0.05) | In all patient groups, continence was achieved in 72% at 1 year postoperatively | No significant difference between groups at 1 year |
| Ocampo-Trujillo et al. (2014) ²³¹ | RCT | Supervised PFMT, 3 times/day for 4 weeks preoperatively with biofeedback (n=8) | Routine pre-surgical education (dietary and general health measures) (n=8) | 8 weeks | No pads at the time of catheter removal postoperatively: intervention: 75%; control: 25% (P=NS); continence defined as 0 g on 3 consecutive 24-h pad tests | Small study (n=16); short follow-up period | No significant difference between groups at the time of catheter removal, but changes in the histology and function of the PFMs were identified |
| Patel et al. (2013) ¹⁹⁰ | Retrospective | Physiotherapist-guided PFMT with verbal and visual biofeedback for up to 4 weeks preoperatively (n=152) | Verbal instruction about PFME by the surgeon (historical control) (n=132) | 6 weeks and 3 months | 6 weeks: mean 24-h pad weight; intervention: 9 g; control: 17 g (P<0.001) 3 months: intervention: 4 g; control: 2 g (P=0.18); continence defined as <2 g on 24-h pad weight test | Non-randomized | Starting physiotherapist-led PFMT preoperatively reduces the duration and severity of early urinary incontinence |
| Geraerts et al. (2013) ²³² | RCT | Physiotherapist-guided PFMT with digital or EMG biofeedback for 3 weeks preoperatively (n=91) | PFME after catheter removal (n=89) | 1, 3, 6, 12 months | Median time to continence: intervention: 30 days; control: 31 days (P=0.88); time to continence main outcome measure | Short preoperative training period focused on teaching awareness of the PFMs | Standard postoperative continence rehabilitation could not be improved by adding 3 preoperative training sessions of PFME |

Table 3 (cont.) | Trials of prehabilitative PFME programmes versus standard of care

| Refs | Study design | Intervention | Control | Time of postoperative evaluation | Outcomes | Limitations | Authors' conclusions |
|--|--------------|---|--|----------------------------------|---|---|---|
| Tienforti et al. (2012) ²³³ | RCT | One physiotherapist-guided PFMT session the day before surgery with verbal and visual biofeedback and one session upon catheter removal; monthly sessions thereafter (n = 16) | Oral and written instructions on Kegel exercises after catheter removal (n = 16) | 1, 3, 6 months | 6 months: intervention: 10/16 patients continent; control: 1/16 patients continent (P = 0.002); continence defined as ICIQ-UI score = 0 | Only one preoperative session and on the day before surgery | Preoperative PFMT with monthly postoperative PFME sessions is significantly more effective than the standard of care in improving continence recovery |
| Centemero et al. (2010) ¹⁶⁹ | RCT | Physiotherapist-guided PFMT with verbal and visual feedback starting 30 days preoperatively (n = 59) | Postoperative PFME (n = 59) | 1 and 3 months | 1 month: intervention: 44.1% continent; control: 20.3% (P = 0.018); 3 months: intervention: 59.3% continent; control: 37.3% (P = 0.028); continence defined as no urinary leakage reported in patient's bladder diary and a negative stress test | Short follow-up | Preoperative PFME may improve early continence and QoL after RP but might not change the long-term outcome |
| Dubbelman et al. (2010) ²³⁴ | RCT | Information folder 1 day preoperatively and 9 physiotherapist-guided PFMT sessions postop (n = 34) | Information folder only (n = 36) | 1, 4, 6, 12, 26 weeks | 6 months: intervention: 30% continent; control: 27% continent; continence defined as urine loss of <1 g at 1-h pad test and <4 g on 24 h pad test | Information starting 1 day preoperatively | No significant difference between trial arms |
| Burgio et al. (2006) ²³⁵ | RCT | Single preoperative session of physiotherapist-guided PFMT with visual biofeedback and rectal probe (n = 63) | Postoperatively PFME (n = 62) | 6 weeks, 3 and 6 months | Intervention: median time to continence 3.5 months; control: median time to continence >6 months (P = 0.04); 6 months; intervention: severe/continual leakage; intervention: 5.9%; control: 19.6% (P = 0.04); continence defined as 3 consecutive weekly 1-day diaries that showed no leakage, or a completed 7-day diary with no leakage | Single preoperative session | Preoperative behavioural training can increase the recovery or urinary control and decrease the severity of incontinence following RP |
| Parekh et al. (2003) ²³⁶ | RCT | Physiotherapist-guided PFMT (2 sessions preoperatively, every 3 weeks for 3 months postoperatively after catheter removal) with verbal cues, visual biofeedback, digital palpation and EMG rectal probes (n = 19) | No formal PFME instructions | 6, 12, 16, 20, 28, 52 weeks | 12 weeks: intervention: 13 (68%) continent; control: 7 (37%) (P < 0.05); median time to continence: intervention: 12 weeks; control: 16 weeks (P < 0.05); continence defined as needing 0 to 1 pad/day | Small sample size | Starting physiotherapist-led PFMT preoperatively leads to earlier return of urinary control |
| Bales et al. (2000) ²³⁷ | RCT | Graded PFMT before and after surgery and with biofeedback by a trained nurse (anal pressure probe or perineal patch electromyography) for 2–4 weeks preoperatively (n = 50) | Written and brief verbal instructions in PFME before and after surgery (n = 50) | 1, 2, 3, 4, 6 months | 6 months: intervention: 94% continent; control: 96% (P = 0.596); continence defined as ≤1 pad/day | Patients received only one preoperative biofeedback session. Method of biofeedback (surface electrodes) | Preoperative biofeedback training did not improve urinary continence overall or the rate of return of continence in men undergoing RP |

EMG, electromyography; ICIQ-UI, International Consultation on Incontinence–Urinary Incontinence; NS, not significant; PFME, pelvic floor muscle exercise; PFMs, pelvic floor muscles; PFMT, pelvic floor muscle training; QoL, quality of life; RCT, randomized controlled trial; RP, radical prostatectomy; TPUS, transperineal ultrasound.

with training programmes starting more than 4 weeks before surgery (TABLE 3). Two systematic reviews and meta-analyses have pooled the results from these studies: Chang et al. (7 studies of preoperative PFMEs)³⁸ and Hall et al. (15 studies: 5 preoperative PFMEs, 10 postoperative PFMEs)¹⁵⁶. In the 2016 review of seven studies, Chang et al. reported a 36% improvement in continence at 3 months in men who performed preoperative PFMEs compared with control patients, most of whom received usual care (OR for incontinence 0.64; 95% CI 0.47–0.88, $P=0.005$). However, no significant difference was observed in the continence recovery outcomes between intervention and control groups 6 months after surgery³⁸. These data suggest that the types of preoperative PFME and the way in which PFMT is delivered in these studies might be critical to hastening the recovery of continence and decreasing the duration and severity of the postprostatectomy incontinence symptoms^{38,170}. The time taken to return to continence is critical for the patients' perceived quality of life and psychosocial functioning after radical prostatectomy³⁸. Similarly, a 2020 systematic review and meta-analysis that included 15 RCTs of PFMT delivered preoperatively or postoperatively concluded that commencing PFMT preoperatively reduced incontinence at 3 months (RR 0.76, 95% CI 0.63–0.92, $P=0.006$), whereas postoperative PFMT was not significantly associated with reduced incontinence (RR 0.90, 95% CI 0.79–1.02, $P=0.10$)¹⁵⁶. Deconstructing the details of the PFME or PFMT programme design of the included studies showed that the PFME training was particularly efficacious if commenced preoperatively (as opposed to postoperatively), if it included some form of biofeedback as an adjunct and if the training instructions focused on the urethra (striated urethral sphincter), as opposed to the anus (anal sphincter and puborectalis)¹⁵⁶. Taken together, the evidence to date would suggest that preoperative delivery of a PFMT programme can reduce the time to continence where the potential benefits outweigh the risks. To provide further evidence, a randomized trial (MaTchUP) comprising 363 men has commenced in Australia. The study compares three groups who receive treatment supervised by a physiotherapist commencing 1–2 weeks prior to surgery and postoperatively after removal of the urinary catheter. The first group will receive an individualized PFMT programme, including urethral instruction and training strategies incorporating transperineal ultrasonography visual biofeedback. The second group will receive conventional PFME training focused on muscles around the anus with digital rectal examination and biofeedback. The third group is a control group that will receive no specific training and will be provided with written educational material and online resources only¹⁷⁰. This trial is expected to be completed in 2022.

Patient instruction, training and biofeedback

PFMT programmes can be delivered by health-care professionals, for example, physiotherapists with a special interest and training in men's health and a scope of practice that includes continence management. A 2019 meta-analysis comprising 22 studies reported that PFMT delivered by a health professional and/or

physiotherapist led to faster recovery and increased odds of becoming continent at 1, 3, 4 and 12 months after radical prostatectomy, compared with controls (most control groups comprised either verbally instructed PFMEs starting postoperatively or no PFMEs): OR and 95% CI at 1, 3, 4, 6, 12 months postoperatively: 1 month 2.79 (1.53–5.07), $P=0.0008$ (10 studies), 3 months 2.80 (1.87–4.19), $P<0.0001$ (19 studies), 4 months 2.93 (1.19–7.22), $P=0.02$ (7 studies), 6 months 4.11 (2.24–7.55), $P<0.0001$ (17 studies) and 12 months 2.41 (1.33–4.36), $P=0.004$ (11 studies)¹⁷¹.

PFMT currently consists of intermittent, voluntary contractions of the striated urethral sphincter, levator ani and bulbospongiosus (also known as bulbocavernosus) muscles¹⁷². Three synergistic voluntary pelvic floor muscle activation strategies can contribute to increased urethral pressure: striated urethral sphincter-dominant, levator ani-dominant, and both striated urethral sphincter and levator ani^{85,173}. Whether a particular pelvic floor synergistic strategy is associated with a differential risk of postprostatectomy incontinence is not known. However, the extent of the shortening of the striated urethral sphincter during voluntary contractions is reported to be important for managing postprostatectomy incontinence^{85,157}. Traditionally, PFMT programmes have targeted global activation of the pelvic floor musculature, often with a focus on the anal sphincter area rather than specific striated urethral sphincter activation and training strategies¹³⁹. It has been suggested that a greater focus should be placed on striated urethral sphincter activation and training strategies to compensate for any loss of smooth and striated muscle after prostatectomy¹⁵⁷.

Voluntarily contracting and training the pelvic floor musculature is a novel task for most men, as it involves anatomically remote musculature that are not often contracted or specifically trained in an isolated voluntary manner. Biofeedback has become an important component of comprehensive instruction for pelvic floor muscle activation. Biofeedback involves the use of visual, auditory and/or tactile strategies designed to increase the patient's awareness and understanding of pelvic floor muscle function. A 2016 systematic review and meta-analysis of RCTs reported that biofeedback-assisted PFME training led to statistically significant improvements in urinary continence at 3 and 6 months and beyond 6 months, compared with PFMT without biofeedback (mean effect size -0.23 , 95% CI -0.44 to -0.02 , $P=0.034$ and -0.28 , 95% CI -0.47 to -0.08 , $P=0.005$, respectively, where 0.20 is considered a small effect size and 0.50 a medium effect size)¹⁷⁴. Including biofeedback in PFME instruction and training is important to enable the patient to correctly learn how to contract the pelvic floor muscles and acquire the necessary motor skills to practise correctly. Learning to contract the pelvic floor muscles voluntarily can occur in three main phases that include the following: a cognitive phase whereby the patient understands what needs to occur, an associative phase where improved voluntary pelvic floor muscle performance occurs through instruction, feedback and correct practice and an autonomous phase whereby each patient correctly trains the pelvic floor muscles with the




Fig. 4 | **Components of a progressive pelvic floor exercise training programme.** The stepwise approach of a muscle training programme before radical prostatectomy.

expectation that improved motor performance transfers into functional tasks, facilitating the return to continence following radical prostatectomy¹⁷⁵.

Many health-care professionals falsely assume that patients will correctly contract the pelvic floor musculature when given verbal instructions and/or written materials to do so. Clinical trials have used a range of different verbal instructions to teach patients how to contract the pelvic floor muscles¹³⁹. Different verbal instructions given to patients can alter the activation patterns of the individual pelvic floor muscles and in turn the efficacy of prescribed PFMT programmes¹⁷⁶. Instructions focusing on dorsal retraction of the penis such as ‘shorten your penis’, and urethral closure such as ‘imagine you are stopping the flow of urine midstream’ encourage improved activation of the striated urethral sphincter¹⁷⁶. Instructions that target anal structures such as ‘tighten around your anus’ predominantly induce anal sphincter activity with accompanying puborectalis activation¹⁷⁶. Targeted verbal instructions together with tactile cues can facilitate relaxation of the superficial abdominal muscles. Relaxing the superficial abdominal muscles can optimize the isolated voluntary activation of the pelvic floor muscles and to minimize any increase in bladder pressure caused by contraction of abdominal and diaphragm muscles; for example, breath holding¹⁵⁷. The physiotherapist could place their hand on the patient’s abdominal musculature to ensure that the patient does not rely on the contraction of their abdominal musculature and breath holding during voluntary activation and training of the pelvic floor musculature.

Traditional methods of providing instruction and biofeedback for pelvic floor muscle instruction and training to reduce urinary incontinence have limitations. One commonly used set of instructions and training biofeedback strategy involves patients observing their urinary flow when voluntarily and repeatedly starting and stopping urination¹⁵⁸. This biofeedback method for pelvic floor muscle instruction and training is not recommended and can result in incomplete bladder voiding,

increased post-void residual volume and risk of urinary tract infection¹⁷⁷. Perineometry incorporates the use of an anal pressor sensor to teach and confirm the correct activation of the pelvic floor muscles. Digital rectal examination also continues to be used to assess pelvic floor activation and function. The most commonly used assessment scale during a digital rectal examination is the Modified Oxford Scale (0 = no contraction, 1 = flicker, 2 = weak, 3 = moderate, 4 = good, 5 = strong). However, the subjective nature of clinicians’ evaluation and use of the scale has led to measurement bias. Evidence does not support the Modified Oxford Scale as a reliable and valid method of measuring and differentiating pelvic floor muscle activation, strength and function¹⁷⁸. Although perineometry and digital rectal examination are used to measure pelvic floor muscle strength, neither provides a valid and reliable measure of striated urethral sphincter and bulbocavernosus function¹⁵⁷. In addition, perineometry and digital rectal examinations are invasive and typically not well tolerated and the measurements are often unreliable^{168,179,180}. The limitations of perineometry and digital rectal examination have led to the development of non-invasive real-time transabdominal and transperineal ultrasonography for instruction and training of the pelvic floor musculature.

A progressive patient-centred PFMT programme can incorporate a stepwise approach (FIG. 4). Teaching and training pelvic floor muscle function preoperatively can commence with isolated pelvic floor muscle contractions in stationary positions (supine, sitting and standing). The patient can progress to training the pelvic floor musculature during more complex dynamic tasks where men are likely to experience postprostatectomy incontinence symptoms including coughing, lifting weighted objects, sitting to standing and when walking^{49,157,170}. Training men to consciously activate, coordinate and correctly time voluntary pelvic floor muscle contractions is essential to increase and maintain urethral closure pressure in order to avoid urinary leakage following radical prostatectomy¹⁵⁷.

Activation of the pelvic floor musculature opposes the increase in the intra-abdominal and bladder pressure. An increase in intra-abdominal pressure increases bladder pressure and displaces the bladder base, including the urethrovesical junction, prostate and anorectal junction^{85,181}. Striated urethral sphincter function also increases proportionally with intra-abdominal pressure to increase urethral pressure¹⁸². Thus, preoperative PFMT specifically includes an anticipatory contraction of the pelvic floor musculature before the predictable increase in intra-abdominal pressure with functional tasks. Hypertrophy of the striated pelvic floor musculature and/or the increased strength, endurance and coordination of the muscles is suggested to improve urethral sphincter constriction^{157–159}.

The efficacy of PFME and PFMT programmes can depend on the standardization and quality of verbal instructions given to the patients. For example, instructions such as ‘retract your penis’ and ‘elevate your bladder’ will predominantly activate the striated urethral sphincter and puborectalis muscles, respectively¹⁷⁶. The effect of different PFMT verbal instructions has been reported in healthy continent men aged 28–44 years in a sitting position, rather than in patients prior to prostatectomy and patients with postprostatectomy incontinence, potentially limiting the applicability of these data¹⁷⁶. Furthermore, using the phrase ‘shorten your penis’ might be insensitive wording for men who are affected by postoperative penile shortening, which occurs in 15–68% of men following prostatectomy¹⁸³ and can affect self-esteem and quality of life¹⁸⁴. Relying on the use of terms encouraging penile shortening to facilitate striated urethral sphincter function can be stress-inducing and, potentially, less effective. Alternative patient-centred instructions such as ‘draw your penis towards you as if you are stopping the flow of urine’ or ‘lift your scrotum upwards and retract your penis towards your stomach’ might be more suitable. The delivery and effectiveness of verbal instructions given to each patient by clinicians can be assessed using a non-invasive real-time transperineal ultrasonography examination. Transperineal ultrasonography will visually determine the translation of patient-centred instructions given by clinicians for the patient to perform the required pelvic floor muscle activation strategy. Although instructions can be standardized, patient-specific characteristics may require refinement to achieve the required pelvic floor muscle activation strategy.

Application of transperineal ultrasonography

Until 2012 (REF.¹⁸⁵), assessing the components of the male continence mechanism simultaneously and instructing patients to correctly activate the pelvic floor musculature with biofeedback was not possible in routine clinical practice (FIG. 1). Access was restricted anatomically, owing to the deep position of the muscles within the pelvis, and practically, because of a lack of appropriate imaging technologies in routine clinical practice. Although imaging modalities, such as transrectal ultrasonography for anorectal junction movement (puborectalis), transurethral ultrasonography for striated urethral sphincter muscle

contraction^{78,186} and transabdominal ultrasonography for bladder base elevation (levator ani)¹⁸⁷ have been used to observe the movement of single structures during voluntary pelvic floor muscle contractions, the invasiveness of transrectal and transurethral ultrasonography has resulted in limited use in routine clinical practice. However, transperineal ultrasonography enables clinicians to view the dynamic contraction and motion of the striated muscles of the pelvic floor non-invasively in real time both at rest and during voluntary (Supplementary videos 1–3) and involuntary (Supplementary video 4) pelvic floor muscle contractions. Transperineal ultrasonography provides visual biofeedback to patients and clinicians during PFMT instruction and exercise, potentially improving patient learning and increasing the effectiveness of PFMT and PFME programmes. One prospective study reported that transperineal ultrasonography-guided PFMT led to faster recovery time to continence (time to continence in days, transperineal ultrasonography-guided PFMT mean \pm s.d., 76 ± 100 versus no transperineal ultrasonography-guided PFMT 122 ± 132 , $P=0.037$)¹⁸⁸.

Assessment of pelvic floor muscle function

Pelvic floor muscle function can be assessed non-invasively using ultrasonography both preoperatively and postoperatively. Transabdominal ultrasonography has now been superseded by the transperineal approach. The transperineal approach provides visualization of the coordinated function of the striated urethral sphincter, levator ani and bulbocavernosus, and also provides access to the pubic symphysis, which serves as a stable reference landmark for measurements of pelvic floor muscle function¹⁸⁹ (FIG. 5; Supplementary video 1). By contrast, non-invasive transabdominal ultrasonography visualizes the function of the levator ani musculature only (bladder base elevation) with no stable reference landmark for reliable measurements of bladder base displacements during voluntary pelvic floor muscle contractions^{190,191}.

Transperineal ultrasonography has been used in patients to assess and measure pelvic floor muscle function, provide non-invasive visual biofeedback during PFMT and for the measurement of MUL^{85,173,181,185,192}. Transperineal ultrasonography is a well-established, non-invasive imaging modality with multiple applications in urological clinical practice and research, including the assessment of pelvic floor disorders in women¹⁹³. Transperineal ultrasonography enables static and dynamic assessment of the lower urinary tract system, including anorectal structures and for the measurement of MUL^{173,185,192} (FIG. 3). Transperineal ultrasonography can assess the real-time coordinated function of the pelvic floor muscles simultaneously in supine, sitting and standing positions¹⁹⁴, for example, striated urethral sphincter, puborectalis and bulbocavernosus muscles, which influence urethral pressure (Supplementary videos 1 and 2). Furthermore, transperineal ultrasonography is less expensive than MRI investigations for the routine measurement of MUL and is used when MRI is contraindicated¹⁹². Transperineal ultrasonography examinations can be performed at rest (FIG. 5a), during

voluntary PFM contractions (FIG. 5b) (Supplementary videos 1–3) and during other tasks such as coughing (Supplementary video 4) and Valsalva manoeuvres, where timing of the pelvic floor muscle contraction prior to an increase in intra-abdominal pressure can be assessed and specific training strategies for the patient developed^{56,157,181}.

Performing transperineal ultrasonography

Patient preparation for transperineal ultrasonography is minimal. Men should generally consume 300–450 ml of water 30–60 min before the transperineal ultrasonography examination to ensure standardization of bladder volumes and to optimize the ultrasound image^{173,181,192}. A B-mode-capable diagnostic 2D ultrasonography system with cine-loop functionality is required to successfully capture the dynamic nature of the contraction and relaxation phases of pelvic floor muscle contractions in real time and store for subsequent analysis^{173,181,189}. Transperineal ultrasonography is usually performed with conventional curved array probes with frequencies from 3.5 to 7 Hz (REFS^{173,189}) (Supplementary videos 1 and 2). However, a higher frequency linear probe transducer can provide a more focused image of the action and function of the striated urethral sphincter (Supplementary videos 3 and 4).

Minimizing exposure of the genitalia and ensuring that incontinent patients are protected in case of an incontinence episode is essential for patient comfort, privacy and to minimize anxiety. Patients can be dressed in

either a hospital gown or a pair of loose-fitting shorts that provide sufficient access for the placement of the probe onto the perineum. Transperineal ultrasonography examinations can be performed while incontinent patients are wearing an absorbent pad. The absorbent pad can be moved laterally at the perineum to permit access for the placement of the probe. Alternatively, a uridome adhesive sheath, which covers the penis and is connected to a drainage bag, can be considered.

The transperineal ultrasonography probe is covered with ultrasonic gel. For hygiene purposes, non-powdered gloves and plastic wrap cellophane sheets can be used as clinically accessible and cost-effective probe cover options. The transperineal ultrasonography probe cover can be secured around the neck of the probe with an elastic band or adhesive tape. Commercially available non-sterile probe covers can be used. Powdered gloves are not advised, as the powder can cause reverberation, resulting in reduced quality of the transperineal ultrasonography image.

The transperineal ultrasonography probe is aligned and subsequently positioned on the perineum in the midsagittal plane. The patient can assist the clinician with the probe placement on the perineum by manually lifting the scrotum. Once the probe is positioned, the scrotum is then released by the patient. Transperineal ultrasonography imaging can be performed with the patient in a standing position, in a semi-seated position with the legs extended, in a supine position with knees extended or with the knees flexed to 70° (REFS^{173,191,192,194}).

No consensus has been reached regarding the standardized orientation of the transperineal ultrasonography image on the screen. The default ultrasonography image usually appears with the probe at the top of the screen. Inverting the default transperineal ultrasonography image on the screen 180° places the probe and the perineum at the bottom of the screen, with the head of the patient orientated towards the top of the screen (FIG. 5). A caudal (inferior) to cephalad (superior) orientation of the lower urinary tract from the bottom to the top of the screen can assist clinicians and patients with verbal instructions and in the interpretation of the movement of the anatomical structures of interest in real time. For example, the antero-superior elevation of the bladder base and the anorectal junction with a verbal command such as ‘elevate your bladder’ during a voluntary pelvic floor muscle contraction would occur in an upward direction towards the top of the screen (see Supplementary videos 1 and 2). The left-sided or right-sided orientation of the transperineal ultrasonography image on the screen should be determined and clearly designated by each clinical facility to ensure consistency with any anatomical sketches that patients receive in their educational materials.

The main axis of the probe is maintained in the midsagittal plane throughout the transperineal ultrasonography examination. A lateral left-to-right sweep of the transducer is then conducted to obtain a clear image for the identification of the anatomical structures of interest, including the pubic symphysis anteriorly, the bladder, prostate, prostatic and membranous urethra, the penile bulb and anorectal junction (FIG. 3b; supplementary videos 1 and 2).

During voluntary pelvic floor contractions, transperineal ultrasonography shows the coordinated




Fig. 5 | Transperineal ultrasonography of the striated urethral sphincter. Mid-sagittal 2D cine-loop transperineal imaging is used to capture images of the membranous urethra during voluntary pelvic floor muscle contractions. The pubic symphysis is used as a stable bony reference landmark for the position of an x–y axis system to interpret the activity of the striated urethral sphincter as visualized by the displacement of the mid-membranous urethra. **a** | The membranous urethra at rest. **b** | The membranous urethra contracted. The same approach is used for the assessment of the displacement of the anorectal junction (puborectalis muscle) and the penile bulb (bulbocavernosus).

Table 4 | Pelvic floor muscle function observed on transperineal ultrasonography

| Muscle | Observed TPUS movement | TPUS link |
|---|--|------------------------------------|
| Striated urethral sphincter (rhabdosphincter) | Posterior displacement of the mid-membranous urethra | Supplementary videos 1, 2, 3 and 4 |
| Levator ani: encompassing puborectalis, iliococcygeus, pubococcygeus and pubovisceralis | Antero-superior displacement the bladder base (UVJ) | Supplementary videos 1 and 2 |
| Puborectalis | Antero-superior displacement of the ARJ | Supplementary videos 1 and 2 |
| Bulbocavernosus | Anterior compression of the penile bulb | Supplementary videos 1 and 2 |

ARJ, anorectal junction; TPUS, transperineal ultrasound; UVJ, urethrovesical junction.

function of the striated pelvic floor muscles in one image, including the striated urethral sphincter, levator ani, puborectalis and bulbocavernosus (Supplementary videos 1 and 2). The functional interrelationship of the action of these pelvic floor muscles can be captured in a single sagittal plane image sequence of each voluntary pelvic floor muscle contraction. Transperineal ultrasonography can clearly display the antero-superior elevation of the bladder base (specifically the urethrovesical junction) and the anorectal junction, dorsal displacement of the membranous urethra and compression of the bulb of the penis during voluntary pelvic floor muscle contractions. The synchronized movement of the anatomical structures during voluntary pelvic floor muscle contractions has been validated against electromyography (EMG) recordings of the pelvic floor musculature⁵⁶ (TABLE 4; Supplementary videos 1–4).

The relative contribution of each striated muscle group during voluntary pelvic floor muscle contractions can be determined and quantified (TABLE 4; FIG. 5; Supplementary videos 1 and 2). Specifically, capturing the pubic symphysis in the midsagittal images provides a stable bony reference landmark that can be used by a coordinate x, y axis system to measure the displacement of anatomical landmarks¹⁸⁹ (FIG. 5). Studies have reported the use of purpose-built software to analyse and measure the displacement of relevant anatomical landmarks^{173,189}. However, accessible Digital Imaging and Communications in Medicine (DICOM) viewer software packages have the necessary capability and can be used¹⁹².

Measurement of membranous urethral length

MRI is the gold standard for measuring MUL. The clear visualization and cross-referencing of standard sagittal, axial and coronal T2-weighted MR images enables the identification of the apex of the prostate, membranous urethra and penile bulb^{88,195}. However, obtaining preoperative MUL measurements using MRI is not routine in urological practices outside of large-volume centres. MRI investigations are costly, time consuming and resource intensive, requiring specialist technicians and radiologists to perform and evaluate the images. Furthermore, not all patients can undergo MRI owing to claustrophobia or the presence of metal implants. However, a 2018 investigation reported that preoperative MUL can be accurately and reliably measured by transperineal ultrasonography¹⁹²

(Supplementary videos 1 and 2). In this study, transperineal ultrasonography-measured MUL demonstrated excellent agreement with MRI measurements (intra-class correlation in the supine position: 0.93, 95% CI 0.76–0.98), excellent test–retest reliability (intra-class correlation in the supine position 0.97, 95% CI 0.91–0.99) and minimal difference between the two supine position measurements (mean difference of 0.03 mm, limits of agreement 95%: –1.2 to 1.3 mm)¹⁹². Visualization of the MUL in the same patient using transperineal ultrasonography and MRI illustrates the excellent agreement between the two measurements (FIG. 3).

Assessing urinary function outcomes

A variety of methods can be used to assess urinary function in men undergoing radical prostatectomy. When assessing postoperative outcomes, the patient's preoperative baseline function must be considered, in particular the presence of pre-existing preoperative voiding dysfunction. For example, intrinsic sphincter dysfunction or overactive bladder symptoms can be identified and treatment interventions commenced in the prehabilitation period^{52,196,197}. Studies report that patients with poor urinary incontinence and overactive bladder symptom scores before radical prostatectomy also had worsening of symptom scores at all time points after radical prostatectomy^{95,198–200}.

Pad weight is an objective method recommended by the International Continence Society (ICS) to identify and quantify the severity of urinary incontinence symptoms preoperatively and during the postoperative period²⁰¹. Ideally, 24-h pad weight is assessed for 3 consecutive days coupled with either a voiding diary, in which the patient records his voiding pattern during normal activities, and/or a frequency–volume chart, whereby patients void into a measurement container and the volume and time of each voiding episode is recorded²⁰². The standardized pad weight testing procedures can be explained to patients preoperatively in preparation for the required postoperative testing requirements.

A broadly accepted conservative definition of urinary continence after radical prostatectomy has been pad-free status (no pad use per 24 h in the past week)^{91,203}. Alternative definitions of continence include 'social continence' where pad use is ≤1 pad per day^{91,108}. The evaluation of urinary function directly by clinicians is often inadequate²⁰⁴, requiring the use of validated questionnaires to obtain patient-reported outcome measures²⁰⁵. Validated questionnaires, such as the International Consultation on Incontinence Questionnaire (ICIQ) on Male Lower Urinary Tract Symptoms (ICIQ-MLUTS)^{206,207}, a short form thereof (ICIQ-SF)^{49,203,208}, the Expanded Prostate Cancer Index Composite (EPIC)^{205,209} urinary incontinence domain and the University of California Los Angeles Prostate Cancer Index (UCLA-PCI), have been used²¹⁰.

Patient motivation and compliance

Establishing a regular and consistent pattern of exercise prior to surgery, especially for patients with an inactive lifestyle, can be challenging for patients and clinicians.

Understanding each patient's behavioural and psychosocial enablers, influencers and barriers to exercise is important. Involving the patient in the development of the preoperative treatment plan including exercise interventions and discussing treatment goals enables the patient to be an active participant in the preparation for surgery. As a result, patient compliance with the prescribed management plan is likely to be increased^{211,212}. Patients are similarly motivated to work towards a deadline, in this case the date of surgery when motivation to engage in positive behaviour change is increased^{213,214}.

If the patient is unmotivated, the cause of any physical or psychosocial barriers to participation in the preoperative programme should be investigated and discussed. For example, the ability to undertake weight-bearing aerobic exercise or resistance training could be limited by comorbid degenerative joint disease. Providing patients with specific solution-focused alternatives — such as non-weight-bearing exercise including arm cranking and cycling, modified non-weight-bearing resistance exercise and training options while still using weights and resistance bands — can overcome barriers to participation. A range of approaches, including supervised, group-based, home-based and web-based interventions, have been reported to improve exercise adherence in cancer survivors. Strategies to improve the uptake of preoperative exercise-based interventions include the use of self-reported exercise behaviours supported by objective self-monitoring measurements. The setting of specific measurable goals and a graded patient-centred approach to increasing the exercise duration and intensity can improve exercise adherence before radical prostatectomy²¹⁵.

The efficacy of verbal and written instructions to promote behavioural change during the preoperative period can depend on how the instructions are framed: messages that stress the benefits of engaging in physical exercise interventions and PFMT programmes before surgery (gain-framed messages) can be more effective than messages that focus on the disadvantages of non-participation (loss-framed messages)^{216,217}. According to health behaviour change theory, an increase in the belief that exercise can deliver greater positive outcomes (a more rapid return to continence and a greater ability to cope with surgery) can lead to positive changes in a person's behaviour^{218,219}. In populations that do not have a cancer diagnosis, those who expect more positive and fewer negative outcomes from exercise have a stronger commitment to engage in exercise and increase the amount of physical activity they undertake²²⁰. Clinicians could use gain-framed scripted phrases, such as “Increasing your physical activity levels and doing PFMT correctly and effectively before surgery will give the surgeon the best possible patient to operate on and improve your recovery” and “the preoperative PFMT programme will give you peace of mind knowing that you are doing everything you can to prepare well for surgery, which can reduce the impact of the predictable urinary incontinence symptoms”.

Technology has increasingly become part of aerobic exercise training programmes and PFMT programmes, in particular the use of patient-friendly

smartphone applications and wearable devices. Accessible activity-tracking devices can be recommended to patients to enable the quantification of their physical activity and habitual exercise. These smartphone and wearable devices can also provide clinicians with objective data with which to assess patient compliance, the effects of different interventions, to adjust the exercise prescription and as a motivator for positive behaviour change^{221,222}. In a non-randomized study of 112 patients undergoing prostatectomy, a communication tool between the patient and the health-care professional replaced in-person clinical follow-up visits with an instructional PFMT video and automated reminders to do the exercise programme. This change in communication mode led to a significant decrease in urinary leakage at 1–3 months compared with PFME alone (24-h pad test (g): mean \pm s.d. 254 ± 76 in the intervention group versus 293 ± 86 in the control group at 1 month, $P < 0.05$, and mean 76 ± 47 versus 98 ± 58 at 3 months, $P < 0.05$)²²³.

A culture of multidisciplinary prehabilitation

When a patient presents with newly diagnosed localized prostate cancer and meets with the surgeon to discuss the available treatment options, the conversation often focuses on cancer control and long-term mortality rather than the risks and management of postoperative complications. Shared decision-making consultations that discuss the management plan to proceed with radical prostatectomy can be an important teachable moment, whereby the surgeon and their multidisciplinary team can inform the patient about the risk profile for postprostatectomy incontinence, the positive effect of preoperative PFMT programmes and the importance of engaging in physical exercise in the lead-up to and after surgery. The date of surgery presents the patient with a clearly defined timeline, from the start of the preoperative intervention to the day of surgery, and can act as a motivator for positive behaviour change during the preoperative period and after surgery²¹⁴.

When the surgeon informs and reinforces the requirement for the patient to participate in the defined preoperative programme to reduce postprostatectomy incontinence, they become an important enabler for the commitment to, and delivery of, preoperative PFMT, and act as a key motivating factor^{224,225}. Patients need to be informed by the surgeon and their multidisciplinary team about the benefits of structured exercise programmes on continence and oncological outcomes. For example, obesity (BMI ≥ 30) is significantly associated with additional risk of urinary incontinence at 12 months after prostatectomy (OR 2.43, 95% CI 1.57–2.56)¹⁰⁶. A qualitative interview study with urological oncology surgeons, patients and physiotherapists reported that a recommendation for preoperative PFMT from the surgeon, and a referral to a specific provider, were key enablers for the acceptance, commitment to and delivery of preoperative PFMT²²⁵. Effective verbal communication of information about the preoperative plan, supplemented with written materials, can assist the transfer of knowledge to the patient during consultations and throughout the preoperative period. The use of a preoperative checklist can facilitate patient engagement

in the preoperative phase of care and the surgeon's specific plan of management²²⁴.

Establishing and maintaining a culture of multidisciplinary health-care delivery can benefit patients who are participating in an effective 'team-based approach' to surgical cancer care²²⁶. By consistently reinforcing the surgeon's referral for preoperative exercise interventions, including PFMT and exercise, the multidisciplinary team can continue to build a culture of prehabilitation and facilitate the defined preoperative surgical pathway²²⁷. To establish a culture of evidence-based prehabilitation, the multidisciplinary team members can be presented with a summary of the evidence that identifies the effectiveness of preoperative PFME and/or PFMT on postprostatectomy incontinence. An evidence-based summary can be an important starting point for discussions with patients when proposing the change to a preparatory preoperative prehabilitation model of care rather than a reactionary postoperative rehabilitation model of care²²⁴.

Despite committing to a multidisciplinary team approach, the surgeon is key to the success of the preoperative and postoperative interventions^{224,225}. Patients report that referral to preoperative PFMT programmes should be the domain of the surgeon²²⁵. The advice, recommendation and/or mandate of the surgeon influences the patient's decision-making prior to radical prostatectomy²²⁵. Surgeons are well placed to assume the leadership role for determining and reinforcing a comprehensive model of care that incorporates preoperative exercise-based strategies, including preoperative PFMT programmes²²⁵. Urology practices and departments should be able to refer patients to providers of preoperative PFMT programmes, for example, physiotherapists, who have a scope of practice to deliver a level of care expected by the surgeon and achieve the goals set for each patient²²⁵.

Conclusions

Physical exercise interventions including aerobic exercise, resistance training and preoperative PFME and/or PFMT programmes can positively influence physical and psychosocial outcomes in patients who have undergone radical prostatectomy. The intent of designing and prescribing an appropriate preoperative exercise stimulus is to impose a sustained physiological challenge that will result in beneficial physiological adaptations at the individual muscle level and across the urological, cardiovascular, respiratory, musculoskeletal, neurological, metabolic and endocrine body systems. Establishing a consistent pattern of exercise before surgery can be challenging for both patients and clinicians. Thus, understanding individual patient behavioural and psychosocial enablers, influencers and barriers to exercise makes an important contribution to the success of the preoperative programme. A structured and coordinated prehabilitation model of care that is led by the surgeon and delivered through their multidisciplinary team can act as an extension of the care provided by the surgeon. A strong recommendation and mandate by the surgeon and referral to specific providers with the required scope of practice is an important enabler for the success of preoperative PFME and/or PFMT interventions. The implementation of transperineal ultrasonography provides a non-invasive and validated method to improve the quality and effectiveness of the delivery of PFME and/or PFMT interventions in men before radical prostatectomy. Collectively, exercise-based interventions before and after prostatectomy have the potential to extend the care that is provided by the surgeon to facilitate optimal preoperative and postoperative functional outcomes for the patient.

Published online 8 April 2021

- Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* <https://doi.org/10.3322/caac.21660> (2021).
- Culp, M. B., Soerjomataram, I., Efstathiou, J. A., Bray, F. & Jemal, A. Recent global patterns in prostate cancer incidence and mortality rates. *Eur. Urol.* **77**, 38–52 (2020).
- Hilal, L. et al. Prostate cancer in the Arab World: a view from the inside. *Clin. Genitourin. Cancer* **13**, 505–511 (2015).
- Al-Abdin, O. Z. & Al-Beeshi, I. Z. Prostate cancer in the Arab population. An overview. *Saudi Med. J.* **39**, 453–458 (2018).
- Sierra, M. S. et al. Cancer patterns and trends in Central and South America. *Cancer Epidemiol.* **44** (Suppl. 1), S23–S42 (2016).
- Klotz, L. Active surveillance for low-risk prostate cancer. *Curr. Opin. Urol.* **27**, 225–230 (2017).
- Scardino, P. T., Linehan, W. M., Zelefsky, M. J. & Vogelzang, N. J. *Comprehensive Textbook of Genitourinary Oncology* 4th edn Ch. 8 (eds Loeb, S. and Catalona, W. J.) 66–74 (Lippincott Williams & Wilkins, 2011).
- Pennney, K. L. et al. Gleason grade progression is uncommon. *Cancer Res.* **73**, 5163–5168 (2013).
- Sanda, M. G. et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part 1: risk stratification, shared decision making, and care options. *J. Urol.* **199**, 683–690 (2018).
- Lovf, M. et al. Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity. *Eur. Urol.* **75**, 498–505 (2019).
- Cooperberg, M. R. et al. The diverse genomic landscape of clinically low-risk prostate cancer. *Eur. Urol.* **74**, 444–452 (2018).
- Bancroft, E. K. et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. *Eur. Urol.* **66**, 489–499 (2014).
- Lavery, H. J. & Cooperberg, M. R. Clinically localized prostate cancer in 2017: a review of comparative effectiveness. *Urol. Oncol.* **35**, 40–41 (2017).
- Garisto, J. D. & Klotz, L. Active surveillance for prostate cancer: how to do it right. *Oncology* **31**, 333–340, 345 (2017).
- Cooperberg, M. R. & Carroll, P. R. Trends in management for patients with localized prostate cancer, 1990–2013. *JAMA* **314**, 80–82 (2015).
- Ahdoot, M., Lebastchi, A. H., Turkbey, B., Wood, B. & Pinto, P. A. Contemporary treatments in prostate cancer focal therapy. *Curr. Opin. Oncol.* **31**, 200–206 (2019).
- Fahmy, O., Khairul-Asri, M. G., Hadi, S., Gakis, G. & Stenzl, A. The role of radical prostatectomy and radiotherapy in treatment of locally advanced prostate cancer: a systematic review and meta-analysis. *Urol. Int.* **99**, 249–256 (2017).
- James, N. D. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. *Lancet* **387**, 1163–1177 (2016).
- Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. *N. Engl. J. Med.* **373**, 757–766 (2015).
- James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. *N. Engl. J. Med.* **377**, 338–351 (2017).
- Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. *N. Engl. J. Med.* **377**, 352–360 (2017).
- Mandel, P., Steuber, T. & Graefen, M. Radical prostatectomy in oligometastatic prostate cancer. *Curr. Opin. Urol.* **27**, 572–579 (2017).
- Costello, A. J. Considering the role of radical prostatectomy in 21st century prostate cancer care. *Nat. Rev. Urol.* **17**, 177–188 (2020).
- Young, H. H. The early diagnosis and radical cure of carcinoma of the prostate. Being a study of 40 cases and presentation of a radical operation which was carried out in four cases. 1905. *J. Urol.* **167**, 939–946; discussion 947 (2002).
- Bill-Axelsson, A. et al. Radical prostatectomy or watchful waiting in prostate cancer — 29-year follow-up. *N. Engl. J. Med.* **379**, 2319–2329 (2018).
- Hamdy, F. C. et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. *N. Engl. J. Med.* **375**, 1415–1424 (2016).
- Sanda, M. G. et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. *N. Engl. J. Med.* **358**, 1250–1261 (2008).
- Mungovan, S. F., Huijbers, B. P., Hirschhorn, A. D. & Patel, M. I. Relationships between perioperative physical activity and urinary incontinence after radical prostatectomy: an observational study. *BMC Urol.* **13**, 67 (2013).
- Hoffman, K. E. et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. *JAMA* **323**, 149–163 (2020).
- Sultan, R., Slova, D., Thiel, B. & Lepor, H. Time to return to work and physical activity following open radical retropubic prostatectomy. *J. Urol.* **176**, 1420–1423 (2006).
- Jayadevappa, R. et al. The burden of out-of-pocket and indirect costs of prostate cancer. *Prostate* **70**, 1255–1264 (2010).

32. Dahl, S., Cvanarova, M., Dahl, A. A. & Fossa, S. D. Work ability in prostate cancer survivors after radical prostatectomy. *Scand. J. Urol.* **50**, 116–122 (2016).

33. Punnen, S., Cowan, J. E., Chan, J. M., Carroll, P. R. & Cooperberg, M. R. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. *Eur. Urol.* **68**, 600–608 (2015).

34. Patel, V. R. et al. Critical review of ‘pentapecta’ outcomes after robot-assisted laparoscopic prostatectomy in high-volume centres. *BJU Int.* **108**, 1007–1017 (2011).

35. Walsh, P. C., Lepor, H. & Eggleston, J. C. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. *Prostate* **4**, 473–485 (1983).

36. Walsh, P. C. & Donker, P. J. Impotence following radical prostatectomy: insight into etiology and prevention. *J. Urol.* **128**, 492–497 (1982).

37. Walz, J. et al. A critical analysis of the current knowledge of surgical anatomy of the prostate related to optimisation of cancer control and preservation of continence and erection in candidates for radical prostatectomy: an update. *Eur. Urol.* **70**, 301–311 (2016).

38. Chang, J. I., Lam, V. & Patel, M. I. Preoperative pelvic floor muscle exercise and postprostatectomy incontinence: a systematic review and meta-analysis. *Eur. Urol.* **69**, 460–467 (2016).

39. Hill, W. G. Control of urinary drainage and voiding. *Clin. J. Am. Soc. Nephrol.* **10**, 480–492 (2015).

40. Griffiths, D. Neural control of micturition in humans: a working model. *Nat. Rev. Urol.* **12**, 695–705 (2015).

41. de Groat, W. C., Griffiths, D. & Yoshimura, N. Neural control of the lower urinary tract. *Compr. Physiol.* **5**, 327–396 (2015).

42. Sadananda, P., Vahabi, B. & Drake, M. J. Bladder outlet physiology in the context of lower urinary tract dysfunction. *NeuroUrol. Urodyn.* **30**, 708–713 (2011).

43. Fowler, C. J., Griffiths, D. & de Groat, W. C. The neural control of micturition. *Nat. Rev. Neurosci.* **9**, 453–466 (2008).

44. Keller, J. A. et al. Voluntary urination control by brainstem neurons that relax the urethral sphincter. *Nat. Neurosci.* **21**, 1229–1238 (2018).

45. de Groat, W. C. & Wickens, C. Organization of the neural switching circuitry underlying reflex micturition. *Acta Physiol.* **207**, 66–84 (2013).

46. Kalejaiye, O., Vij, M. & Drake, M. J. Classification of stress urinary incontinence. *World J. Urol.* **33**, 1215–1220 (2015).

47. Resnick, M. J. et al. Long-term functional outcomes after treatment for localized prostate cancer. *N. Engl. J. Med.* **368**, 436–445 (2013).

48. Johansson, E. et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. *Lancet Oncol.* **12**, 891–899 (2011).

49. Mungovan, S. F., Huijbers, B. P., Hirschhorn, A. D. & Patel, M. I. What makes men leak? An investigation of objective and self-report measures of urinary incontinence early after radical prostatectomy. *NeuroUrol. Urodyn.* **35**, 225–229 (2016).

50. Boorjian, S. A. et al. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. *Eur. Urol.* **61**, 664–675 (2012).

51. Krupski, T. L., Saigal, C. S. & Litwin, M. S. Variation in continence and potency by definition. *J. Urol.* **170**, 1291–1294 (2003).

52. Chung, E., Katz, D. J. & Love, C. Adult male stress and urge urinary incontinence — a review of pathophysiology and treatment strategies for voiding dysfunction in men. *Aust. Fam. Physician* **46**, 661–666 (2017).

53. Thuroff, J. W. et al. EAU guidelines on urinary incontinence. *Eur. Urol.* **59**, 387–400 (2011).

54. Sacco, E. et al. Urinary incontinence after radical prostatectomy: incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. *BJU Int.* **97**, 1234–1241 (2006).

55. Medina-Polo, J. et al. Correlation between symptoms and urodynamic results in patients with urinary incontinence after radical prostatectomy. *Arch. Esp. Urol.* **71**, 523–530 (2018).

56. Stafford, R. E., Coughlin, G., Lutton, N. J. & Hodges, P. W. Validity of estimation of pelvic floor muscle activity from transperineal ultrasound imaging in men. *PLoS One* **10**, e0144342 (2015).

57. Donovan, J. L. et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. *N. Engl. J. Med.* **375**, 1425–1437 (2016).

58. Palmer, M. H., Fogarty, L. A., Somerfield, M. R. & Powel, L. L. Incontinence after prostatectomy: coping with incontinence after prostate cancer surgery. *Oncol. Nurs. Forum* **30**, 229–238 (2003).

59. Carrier, J., Edwards, D. & Harden, J. Men’s perceptions of the impact of the physical consequences of a radical prostatectomy on their quality of life: a qualitative systematic review. *JBI Database Syst. Rev. Implement. Rep.* **16**, 892–972 (2018).

60. Brown, J. A., Elliott, D. S. & Barrett, D. M. Postprostatectomy urinary incontinence: a comparison of the cost of conservative versus surgical management. *Urology* **51**, 715–720 (1998).

61. Elliott, P. A. et al. Healthcare utilization in men with poorer sexual and urinary function recovery following robot-assisted radical prostatectomy. *World J. Urol.* **36**, 21–26 (2018).

62. Strasser, H., Ninkovic, M., Hess, M., Bartsch, G. & Stenzl, A. Anatomic and functional studies of the male and female urethral sphincter. *World J. Urol.* **18**, 324–329 (2000).

63. Heesakkers, J. et al. Pathophysiology and contributing factors in postprostatectomy incontinence: a review. *Eur. Urol.* **71**, 936–944 (2017).

64. Pavlovich, C. P., Rocco, B., Druskin, S. C. & Davis, J. W. Urinary continence recovery after radical prostatectomy - anatomical/reconstructive and nerve-sparing techniques to improve outcomes. *BJU Int.* **120**, 185–196 (2017).

65. Lavery, H. T. J. et al. Baseline functional status may predict decisional regret following robotic prostatectomy. *J. Urol.* **188**, 2213–2218 (2012).

66. Sandhu, J. S. & Eastham, J. A. Factors predicting early return of continence after radical prostatectomy. *Curr. Urol. Rep.* **11**, 191–197 (2010).

67. Hinata, N. et al. Urethral sphincter fatigue after robot-assisted radical prostatectomy: descriptive questionnaire-based study and anatomic basis. *Urology* **84**, 144–148 (2014).

68. Dubbleman, Y. D. & Bosch, J. L. Urethral sphincter function before and after radical prostatectomy: Systematic review of the prognostic value of various assessment techniques. *NeuroUrol. Urodyn.* **32**, 957–963 (2013).

69. Lee, H. et al. Urodynamic assessment of bladder and urethral function among men with lower urinary tract symptoms after radical prostatectomy: a comparison between men with and without urinary incontinence. *Korean J. Urol.* **56**, 803–810 (2015).

70. Kadono, Y. et al. Urodynamic evaluation before and immediately after robot-assisted radical prostatectomy. *Urology* **84**, 106–111 (2014).

71. Mungovan, S. F. et al. Preoperative membranous urethral length measurement and continence recovery following radical prostatectomy: a systematic review and meta-analysis. *Eur. Urol.* **71**, 368–378 (2017).

72. Cameron, A. P. et al. Functional and anatomical differences between continent and incontinent men post radical prostatectomy on urodynamics and 3T MRI: a pilot study. *NeuroUrol. Urodyn.* **34**, 527–532 (2015).

73. Dubbleman, Y., Groen, J., Wildhagen, M., Rikken, B. & Bosch, R. Quantification of changes in detrusor function and pressure-flow parameters after radical prostatectomy: relation to postoperative continence status and the impact of intensity of pelvic floor muscle exercises. *NeuroUrol. Urodyn.* **31**, 637–641 (2012).

74. Majoros, A., Bach, D., Kesztelyi, A., Hamvas, A. & Romics, I. Urinary incontinence and voiding dysfunction after radical retropubic prostatectomy (prospective urodynamic study). *NeuroUrol. Urodyn.* **25**, 2–7 (2006).

75. Kleinhans, B. et al. Changes of urodynamic findings after radical retropubic prostatectomy. *Eur. Urol.* **35**, 217–221 (1999).

76. Minervini, R., Felipetto, R., Morelli, G., Fontana, N. & Fiorentini, L. Urodynamic evaluation of urinary incontinence following radical prostatectomy: our experience. *Acta Urol. Belg.* **64**, 5–8 (1996).

77. Dalpiaz, O. et al. Anatomical approach for surgery of the male posterior urethra. *BJU Int.* **102**, 1448–1451 (2008).

78. Strasser, H. et al. Three-dimensional transrectal ultrasound of the male urethral rhabdosphincter. *World J. Urol.* **22**, 335–338 (2004).

79. Robain, G., Perrigot, M. & Mazieres, L. Urethral pressure response to cough and voluntary perineal contraction in men without previous pelvic surgery. *NeuroUrol. Urodyn.* **18**, 99–111 (1999).

80. Song, C. et al. Relationship between the integrity of the pelvic floor muscles and early recovery of continence after radical prostatectomy. *J. Urol.* **178**, 208–211 (2007).

81. Desautel, M. G., Kapoor, R. & Badlani, G. H. Sphincter incontinence: the primary cause of post-prostatectomy incontinence in patients with prostate cancer. *NeuroUrol. Urodyn.* **16**, 153–160 (1997).

82. Strasser, H. et al. Transurethral ultrasound: evaluation of anatomy and function of the rhabdosphincter of the male urethra. *J. Urol.* **159**, 100–104; discussion 104–105 (1998).

83. Song, C. et al. Urodynamic interpretation of changing bladder function and voiding pattern after radical prostatectomy: a long-term follow-up. *BJU Int.* **106**, 681–686 (2010).

84. Hammerer, P. & Huland, H. Urodynamic evaluation of changes in urinary control after radical retropubic prostatectomy. *J. Urol.* **157**, 233–236 (1997).

85. Stafford, R. E., van den Hoorn, W., Coughlin, G. & Hodges, P. W. Postprostatectomy incontinence is related to pelvic floor displacements observed with trans-perineal ultrasound imaging. *NeuroUrol. Urodyn.* **37**, 658–665 (2018).

86. Kadono, Y. et al. Changes in penile length after radical prostatectomy: investigation of the underlying anatomical mechanism. *BJU Int.* **20**, 293–299 (2017).

87. Allen, S. D., Thompson, A. & Sohaib, S. A. The normal post-surgical anatomy of the male pelvis following radical prostatectomy as assessed by magnetic resonance imaging. *Eur. Radiol.* **18**, 1281–1291 (2008).

88. Ha, H. K. et al. Three novel methods to measure the postoperative displacement of lower urinary tract structures following radical prostatectomy in a sample of Korean patients. *BMC Urol.* **19**, 54 (2019).

89. Dev, H. S., Sooriakumaran, P., Srivastava, A. & Tewari, A. K. Optimizing radical prostatectomy for the early recovery of urinary continence. *Nat. Rev. Urol.* **9**, 189–195 (2012).

90. Ballenger, E. G. A review of some recent papers on the surgical treatment of prostatic hypertrophy: references. *Medical Record (1866-1922)* **67**, 166 (1905).

91. Matsushita, K. et al. Preoperative predictive model of recovery of urinary continence after radical prostatectomy. *BJU Int.* **116**, 577–583 (2015).

92. Reeves, F. et al. Preservation of the neurovascular bundles is associated with improved time to continence after radical prostatectomy but not long-term continence rates: results of a systematic review and meta-analysis. *Eur. Urol.* **68**, 692–704 (2015).

93. Jones, J. S. et al. Sling may hasten return of continence after radical prostatectomy. *Urology* **65**, 1163–1167 (2005).

94. Dal Moro, F., Crestani, A., Valotto, C. & Zattoni, F. CORPUS — novel complete reconstruction of the posterior urethral support after robotic radical prostatectomy: preliminary data of very early continence recovery. *Urology* **83**, 641–647 (2014).

95. Averbek, M. A. et al. How can we prevent postprostatectomy urinary incontinence by patient selection, and by preoperative, perioperative, and postoperative measures? International Consultation on Incontinence Research Society 2018. *NeuroUrol. Urodyn.* **38** (Suppl. 5), 119–126 (2019).

96. Grasso, A. A. et al. Posterior musculofascial reconstruction after radical prostatectomy: an updated systematic review and a meta-analysis. *BJU Int.* **118**, 20–34 (2016).

97. Vickers, A. J. et al. The surgical learning curve for prostate cancer control after radical prostatectomy. *J. Natl. Cancer Inst.* **99**, 1171–1177 (2007).

98. Vickers, A. J. et al. How do you know if you are any good? A surgeon performance feedback system for the outcomes of radical prostatectomy. *Eur. Urol.* **61**, 284–289 (2012).

99. Bianco, F. J. Jr, Riedel, E. R., Begg, C. B., Kattan, M. W. & Scardino, P. T. Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. *J. Urol.* **173**, 2099–2103 (2005).

100. Bianco, F. J. Jr et al. Variations among experienced surgeons in cancer control after open radical prostatectomy. *J. Urol.* **183**, 977–982 (2010).

101. Begg, C. B. et al. Variations in morbidity after radical prostatectomy. *N. Engl. J. Med.* **346**, 1138–1144 (2002).

102. Vickers, A. et al. Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center. *Eur. Urol.* **59**, 317–322 (2011).

103. Trieu, D., Ju, I. E., Chang, S. B., Mungovan, S. F. & Patel, M. I. Surgeon case volume and continence recovery following radical prostatectomy: a systematic review. *ANZ J. Surg.* <https://doi.org/10.1111/ans.16491> (2020).
104. Strasser, H. et al. Age dependent apoptosis and loss of rhabdosphincter cells. *J. Urol.* **164**, 1781–1785 (2000).
105. Dubbelman, Y. D., Groen, J., Wildhagen, M. F., Rikken, B. & Bosch, J. L. Urodynamic quantification of decrease in sphincter function after radical prostatectomy: relation to postoperative continence status and the effect of intensive pelvic floor muscle exercises. *NeuroUrol. Urodyn.* **31**, 646–651 (2012).
106. Wei, Y. et al. Impact of obesity on long-term urinary incontinence after radical prostatectomy: a meta-analysis. *Biomed. Res. Int.* **2018**, 8279523 (2018).
107. Sridhar, A. N. et al. Surgical techniques to optimize early urinary continence recovery post robot assisted radical prostatectomy for prostate cancer. *Curr. Urol. Rep.* **18**, 71 (2017).
108. Kretschmer, A., Hubner, W., Sandhu, J. S. & Bauer, R. M. Evaluation and management of postprostatectomy incontinence: a systematic review of current literature. *Eur. Urol. Focus* **2**, 245–259 (2016).
109. Santa Mina, D. et al. Prehabilitation for radical prostatectomy: a multicentre randomized controlled trial. *Surg. Oncol.* **27**, 289–298 (2018).
110. Shaughnessy, G., Howard, R. & Englesbe, M. Patient-centered surgical prehabilitation. *Am. J. Surg.* **216**, 636–638 (2018).
111. Carli, F. et al. Surgical prehabilitation in patients with cancer: state-of-the-science and recommendations for future research from a panel of subject matter experts. *Phys. Med. Rehabil. Clin.* **28**, 49–64 (2017).
112. Canadian Institute for Health Information. Wait times. *CIHI* <http://waittimes.cihi.ca/All/prostate?show=5090#year> (2018).
113. Australian Institute of Health and Welfare. Elective surgery waiting times 2016–17. Australian hospital statistics. *AHW* <https://www.aihw.gov.au/getmedia/a7235c2d-3c90-4194-9fa1-b16ed7ff1f0/aihw-hse-197.pdf.aspx?inline=true> (2018).
114. National Prostate Cancer Register. *National Prostate Cancer Register (NPCR) Sweden 2017 — Annual Report* (2018).
115. Australian Institute of Health and Welfare. *Elective Surgery Waiting Times 2017–18. Australian Hospital Statistics* (Australian Institute of Health and Welfare, 2018).
116. Gupta, N. et al. Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate-risk to very-high-risk clinically localised prostate cancer. *BJU Int.* **124**, 268–274 (2018).
117. Lee, D. K., Allareddy, V., O'Donnell M. A., Williams, R. D. & Konety, B. R. Does the interval between prostate biopsy and radical prostatectomy affect the immediate postoperative outcome? *BJU Int.* **97**, 48–50 (2006).
118. Li, R. et al. The use of PET/CT in prostate cancer. *Prostate Cancer Prostatic Dis.* **21**, 4–21 (2018).
119. Naspro, R. & Da Pozzo, L. F. Urology in the time of corona. *Nat. Rev. Urol.* **17**, 251–253 (2020).
120. Campi, R. et al. Assessing the burden of nondeferrable major uro-oncologic surgery to guide prioritisation strategies during the COVID-19 pandemic: insights from three Italian high-volume referral centres. *Eur. Urol.* **78**, 11–15 (2020).
121. Jo, J. K. et al. Can robot-assisted laparoscopic radical prostatectomy (RALP) be performed very soon after biopsy? *World J. Urol.* **35**, 605–612 (2017).
122. Carr, T., Teucher, U., Mann, J. & Casson, A. G. Waiting for surgery from the patient perspective. *Psychol. Res. Behav. Manag.* **2**, 107–119 (2009).
123. Watts, S. et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. *BMJ Open* **4**, e003901 (2014).
124. O'Callaghan, M. E., Shi, Z., Kopsaftis, T. & Moretti, K. Prostate cancer outcomes and delays in care. *Int. Urol. Nephrol.* **49**, 449–455 (2017).
125. Gupta, N. et al. Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate-risk to very-high-risk clinically localised prostate cancer. *BJU Int.* **124**, 268–274 (2019).
126. Reichard, C. A. et al. Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome? *BJU Int.* **124**, 282–289 (2019).
127. Abern, M. R. et al. Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. *Prostate* **73**, 409–417 (2013).
128. Fossati, N. et al. Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: can surgery be postponed safely? *Urol. Oncol.* **35**, 150.e159–150.e115 (2017).
129. Meunier, M. E. et al. Does the delay from prostate biopsy to radical prostatectomy influence the risk of biochemical recurrence? *Prog. Urol.* **28**, 475–481 (2018).
130. Vickers, A. J., Bianco, F. J. Jr, Boorjian, S., Scardino, P. T. & Eastham, J. A. Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence? *Cancer* **106**, 576–580 (2006).
131. Boorjian, S. A., Bianco, F. J. Jr, Scardino, P. T. & Eastham, J. A. Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy? *BJU Int.* **96**, 773–776 (2005).
132. Redaniel, M. T., Martin, R. M., Gillatt, D., Wade, J. & Jeffreys, M. Time from diagnosis to surgery and prostate cancer survival: a retrospective cohort study. *BMC Cancer* **13**, 559 (2013).
133. Ginsburg, K. B., Curtis, G. L., Timar, R. E., George, A. K. & Chien, M. L. Delayed radical prostatectomy is not associated with adverse oncologic outcomes: implications for men experiencing surgical delay due to the COVID-19 pandemic. *J. Urol.* **204**, 720–725 (2020).
134. O'Brien, D. et al. Delay of surgery in men with low risk prostate cancer. *J. Urol.* **185**, 2143–2147 (2011).
135. Berg, W. T. et al. Delay from biopsy to radical prostatectomy influences the rate of adverse pathologic outcomes. *Prostate* **75**, 1085–1091 (2015).
136. Santa Mina, D. et al. The effect of meeting physical activity guidelines for cancer survivors on quality of life following radical prostatectomy for prostate cancer. *J. Cancer Surviv.* **8**, 190–198 (2014).
137. Bock, D. et al. Habits and self-assessed quality of life, negative intrusive thoughts and depressed mood in patients with prostate cancer: a longitudinal study. *Scand. J. Urol.* **51**, 353–359 (2017).
138. Angenete, E. et al. Physical activity before radical prostatectomy reduces sick leave after surgery — results from a prospective, non-randomized controlled clinical trial (LAPPRO). *BMC Urol.* **16**, 50 (2016).
139. Hall, L. M., Aljuraifani, R. & Hodges, P. W. Design of programs to train pelvic floor muscles in men with urinary dysfunction: systematic review. *NeuroUrol. Urodyn.* **37**, 2053–2087 (2018).
140. Strassels, S. et al. Persistent postoperative pain, health-related quality of life, and functioning 1 month after hospital discharge. *Acute Pain.* **6**, 95–104 (2004).
141. Borg, G. *Borg's Perceived Exertion and Pain Scales* (Human Kinetics, 1998).
142. Rock, C. L. et al. Nutrition and physical activity guidelines for cancer survivors. *CA Cancer J. Clin.* **62**, 243–274 (2012).
143. Schmitz, K. H. et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. *Med. Sci. Sports Exerc.* **42**, 1409–1426 (2010).
144. Piercy, K. L. et al. The physical activity guidelines for Americans. *JAMA* **320**, 2020–2028 (2018).
145. Borde, R., Hortobagyi, T. & Granacher, U. Dose-response relationships of resistance training in healthy old adults: a systematic review and meta-analysis. *Sports Med.* **45**, 1693–1720 (2015).
146. Lovell, D. I., Cuneo, R. & Gass, G. C. The effect of strength training and short-term detraining on maximum force and the rate of force development of older men. *Eur. J. Appl. Physiol.* **109**, 429–435 (2010).
147. Santa Mina, D. et al. Prehabilitation for men undergoing radical prostatectomy: a multi-centre, pilot randomized controlled trial. *BMC Surg.* **14**, 89 (2014).
148. Singh, F. et al. Feasibility of presurgical exercise in men with prostate cancer undergoing prostatectomy. *Integr. Cancer Ther.* **16**, 290–299 (2017).
149. Shabataev, V., Saadat, S. H. & Elterman, D. S. Management of erectile dysfunction and LUTS/incontinence: the two most common, long-term side effects of prostate cancer treatment. *Can. J. Urol.* **27**, 17–24 (2020).
150. Sandhu, J. S. et al. Incontinence after prostate treatment: AUA/SUFU Guideline. *J. Urol.* **202**, 369–378 (2019).
151. Kegel, A. H. Progressive resistance exercise in the functional restoration of the perineal muscles. *Am. J. Obstet. Gynecol.* **56**, 238–248 (1948).
152. Bo, K. Physiotherapy management of urinary incontinence in females. *J. Physiother.* **66**, 147–154 (2020).
153. Krauss, D. J., Schoenrock, G. J. & Lilien, O. M. "Reeducation" of urethral sphincter mechanism in postprostatectomy incontinence. *Urology* **5**, 533–535 (1975).
154. Glazener, C. et al. Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following radical prostatectomy or transurethral resection of the prostate (MAPS): two parallel randomised controlled trials. *Lancet* **378**, 328–337 (2011).
155. Zhang, A. Y., Strauss, G. J. & Siminoff, L. A. Effects of combined pelvic floor muscle exercise and a support group on urinary incontinence and quality of life of postprostatectomy patients. *Oncol. Nurs. Forum* **34**, 47–53 (2007).
156. Hall, L. M., Neumann, P. & Hodges, P. W. Do features of randomized controlled trials of pelvic floor muscle training for postprostatectomy urinary incontinence differentiate successful from unsuccessful patient outcomes? A systematic review with a series of meta-analyses. *NeuroUrol. Urodyn.* **39**, 533–546 (2020).
157. Hodges, P. W. et al. Reconsolidation of pelvic floor muscle training to prevent and treat incontinence after radical prostatectomy. *Urol. Oncol.* **38**, 354–371 (2020).
158. Santa Mina, D. et al. A pilot randomized trial of conventional versus advanced pelvic floor exercises to treat urinary incontinence after radical prostatectomy: a study protocol. *BMC Urol.* **15**, 94 (2015).
159. Price, N., Dawood, R. & Jackson, S. R. Pelvic floor exercise for urinary incontinence: a systematic literature review. *Maturitas* **67**, 309–315 (2010).
160. Stafford, R. E., Coughlin, G. & Hodges, P. W. Comparison of dynamic features of pelvic floor muscle contraction between men with and without incontinence after prostatectomy and men with no history of prostate cancer. *NeuroUrol. Urodyn.* **39**, 170–180 (2020).
161. Nambiar, A. K. et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. *Eur. Urol.* **73**, 596–609 (2018).
162. Fernandez, R. A. et al. Improvement of continence rate with pelvic floor muscle training post-prostatectomy: a meta-analysis of randomized controlled trials. *Urol. Int.* **94**, 125–132 (2015).
163. Overgard, M., Angelsen, A., Lydersen, S. & Morkved, S. Does physiotherapist-guided pelvic floor muscle training reduce urinary incontinence after radical prostatectomy? A randomised controlled trial. *Eur. Urol.* **54**, 438–448 (2008).
164. Filocamo, M. T. et al. Effectiveness of early pelvic floor rehabilitation treatment for post-prostatectomy incontinence. *Eur. Urol.* **48**, 734–738 (2005).
165. Van Kampen, M. et al. Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: a randomised controlled trial. *Lancet* **355**, 98–102 (2000).
166. Anderson, C. A. et al. Conservative management for postprostatectomy urinary incontinence. *Cochrane Database Syst. Rev.* **1**, CD001843 (2015).
167. Bauer, R. M. et al. Contemporary management of postprostatectomy incontinence. *Eur. Urol.* **59**, 985–996 (2011).
168. Manassero, F. et al. Contribution of early intensive prolonged pelvic floor exercises on urinary continence recovery after bladder neck-sparing radical prostatectomy: results of a prospective controlled randomized trial. *NeuroUrol. Urodyn.* **26**, 985–989 (2007).
169. Centemero, A. et al. Preoperative pelvic floor muscle exercise for early continence after radical prostatectomy: a randomised controlled study. *Eur. Urol.* **57**, 1039–1043 (2010).
170. Hodges, P. et al. Efficacy of a personalised pelvic floor muscle training programme on urinary incontinence after radical prostatectomy (MaTchUP): protocol for a randomised controlled trial. *BMJ Open* **9**, e028288 (2019).
171. Wu, M. L., Wang, C. S., Xiao, Q., Peng, C. H. & Zeng, T. Y. The therapeutic effect of pelvic floor muscle exercise on urinary incontinence after radical prostatectomy: a meta-analysis. *Asian J. Androl.* **21**, 170–176 (2019).
172. Sandhu, J. S. Treatment options for male stress urinary incontinence. *Nat. Rev. Urol.* **7**, 222–228 (2010).
173. Stafford, R. E., Ashton-Miller, J. A., Constantinou, C. E. & Hodges, P. W. Novel insight into the dynamics of male pelvic floor contractions through transperineal ultrasound imaging. *J. Urol.* **188**, 1224–1230 (2012).
174. Hsu, L. F., Liao, Y. M., Lai, F. C. & Tsai, P. S. Beneficial effects of biofeedback-assisted pelvic floor muscle training in patients with urinary incontinence after radical prostatectomy: a systematic review and metaanalysis. *Int. J. Nurs. Stud.* **60**, 99–111 (2016).

175. Fitts, P. M., & Posner, M. I. *Human Performance* (Brooks/Cole, 1967).
176. Stafford, R. E. et al. Pattern of activation of pelvic floor muscles in men differs with verbal instructions. *NeuroUrol. Urodyn.* **35**, 457–463 (2016).
177. Chesnel, C. et al. Influence of the urine stream interruption exercise on micturition. *Int. J. Urol.* **26**, 1059–1063 (2019).
178. Ferreira, C. H. et al. Inter-rater reliability study of the modified Oxford Grading Scale and the Peritron manometer. *Physiotherapy* **97**, 132–138 (2011).
179. Gomes, C. S. et al. The effects of Pilates method on pelvic floor muscle strength in patients with post-prostatectomy urinary incontinence: a randomized clinical trial. *NeuroUrol. Urodyn.* **37**, 346–353 (2018).
180. Nilssen, S. R., Morkved, S., Overgard, M., Lydersen, S. & Angelsen, A. Does physiotherapist-guided pelvic floor muscle training increase the quality of life in patients after radical prostatectomy? A randomized clinical study. *Scand. J. Urol. Nephrol.* **46**, 397–404 (2012).
181. Stafford, R. E., Mazzone, S., Ashton-Miller, J. A., Constantinou, C. & Hodges, P. W. Dynamics of male pelvic floor muscle contraction observed with transperineal ultrasound imaging differ between voluntary and evoked coughs. *J. Appl. Physiol.* **116**, 953–960 (2014).
182. Stafford, R. E., Ashton-Miller, J. A., Sapsford, R. & Hodges, P. W. Activation of the striated urethral sphincter to maintain continence during dynamic tasks in healthy men. *NeuroUrol. Urodyn.* **31**, 36–43 (2012).
183. Frey, A. U., Sonksen, J. & Fode, M. Neglected side effects after radical prostatectomy: a systematic review. *J. Sex. Med.* **11**, 374–385 (2014).
184. Carlsson, S. et al. Self-perceived penile shortening after radical prostatectomy. *Int. J. Impot. Res.* **24**, 179–184 (2012).
185. Kirschner-Hermanns, R. et al. Two- and three-/four dimensional perineal ultrasonography in men with urinary incontinence after radical prostatectomy. *BJU Int.* **109**, 46–51 (2012).
186. Constantinou, C. E., Damaser, M. S. & Perkash, I. Displacement sequence and elastic properties of anterior prostate/urethral interface during micturition of spinal cord injured men. *Ultrasound Med. Biol.* **28**, 1157–1163 (2002).
187. Doorbar-Baptist, S., Adams, R. & Rebbeck, T. Ultrasound-based motor control training for the pelvic floor pre- and post-prostatectomy: scoring reliability and skill acquisition. *Physiother. Theory Pract.* **33**, 296–302 (2017).
188. Yoshida, M. et al. May perioperative ultrasound-guided pelvic floor muscle training promote early recovery of urinary continence after robot-assisted radical prostatectomy? *NeuroUrol. Urodyn.* **38**, 158–164 (2019).
189. Stafford, R. E., Ashton-Miller, J. A., Constantinou, C. E. & Hodges, P. W. A new method to quantify male pelvic floor displacement from 2D transperineal ultrasound images. *Urology* **81**, 685–689 (2013).
190. Patel, M. I., Yao, J., Hirschhorn, A. D. & Mungovan, S. F. Preoperative pelvic floor physiotherapy improves continence after radical retropubic prostatectomy. *Int. J. Urol.* **20**, 986–992 (2013).
191. Whittaker, J. L., Thompson, J. A., Teyhen, D. S. & Hodges, P. Rehabilitative ultrasound imaging of pelvic floor muscle function. *J. Orthop. Sports Phys. Ther.* **37**, 487–498 (2007).
192. Mungovan, S. F. et al. The measurement of membranous urethral length using transperineal ultrasound prior to radical prostatectomy. *Scand. J. Urol.* **52**, 263–268 (2018).
193. Dietz, H. P. Pelvic floor ultrasound: a review. *Clin. Obstet. Gynecol.* **60**, 58–81 (2017).
194. Cowley, D., Stafford, R. E. & Hodges, P. W. Influence of body position on dynamics of the pelvic floor measured with transperineal ultrasound imaging in men. *NeuroUrol. Urodyn.* **39**, 954–961 (2020).
195. Coakley, F. V. et al. Urinary continence after radical retropubic prostatectomy: relationship with membranous urethral length on preoperative endorectal magnetic resonance imaging. *J. Urol.* **168**, 1032–1035 (2002).
196. Yamada, Y. et al. Overactive bladder is a negative predictor of achieving continence after robot-assisted radical prostatectomy. *Int. J. Urol.* **24**, 749–756 (2017).
197. Neumann, P. B. & O’Callaghan, M. The role of preoperative puborectal muscle function assessed by transperineal ultrasound in urinary continence outcomes at 3, 6, and 12 months after robotic-assisted radical prostatectomy. *Int. NeuroUrol. J.* **22**, 114–122 (2018).
198. Boettcher, M., Haselhuhn, A., Jakse, G., Brehmer, B. & Kirschner-Hermanns, R. Overactive bladder syndrome: an underestimated long-term problem after treatment of patients with localized prostate cancer? *BJU Int.* **109**, 1824–1830 (2012).
199. Ficarra, V. et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. *Eur. Urol.* **62**, 405–417 (2012).
200. Hosier, G. W., Tennankore, K. K., Himmelman, J. G., Gajewski, J. & Cox, A. R. Overactive bladder and storage lower urinary tract symptoms following radical prostatectomy. *Urology* **94**, 193–197 (2016).
201. Abrams, P. et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. *NeuroUrol. Urodyn.* **29**, 213–240 (2010).
202. Abrams, P. et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. *Urology* **61**, 37–49 (2003).
203. Tienza, A. et al. Daily pad usage versus the international consultation on incontinence questionnaire short form for continence assessment following radical prostatectomy. *Int. NeuroUrol. J.* **24**, 156–162 (2020).
204. Wei, J. T. & Montie, J. E. Comparison of patients’ and physicians’ rating of urinary incontinence following radical prostatectomy. *Semin. Urol. Oncol.* **18**, 76–80 (2000).
205. Martin, N. E. et al. Defining a standard set of patient-centered outcomes for men with localized prostate cancer. *Eur. Urol.* **67**, 460–467 (2015).
206. MacKenzie, K. R., Davis, J., Harding, C. & Aning, J. J. Patient-reported outcomes and urodynamic findings in men with persistent lower urinary tract symptoms following robot-assisted radical prostatectomy. *NeuroUrol. Urodyn.* **38**, 1355–1362 (2019).
207. Uren, A. D., Cotterill, N., Parke, S. E. & Abrams, P. Psychometric equivalence of electronic and telephone completion of the ICIQ modules. *NeuroUrol. Urodyn.* **36**, 1342–1349 (2017).
208. Machioka, K. et al. Evaluating urinary incontinence before and after radical prostatectomy using the international consultation on incontinence questionnaire-short form. *NeuroUrol. Urodyn.* **38**, 726–733 (2019).
209. Wei, J. T., Dunn, R. L., Litwin, M. S., Sandler, H. M. & Sanda, M. G. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. *Urology* **56**, 899–905 (2000).
210. Litwin, M. S. et al. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. *Med. Care* **36**, 1002–1012 (1998).
211. Turner, R. R. et al. Interventions for promoting habitual exercise in people living with and beyond cancer. *Cochrane Database Syst. Rev.* **9**, CD010192 (2018).
212. Finlay, A., Wittert, G. & Short, C. E. A systematic review of physical activity-based behaviour change interventions reaching men with prostate cancer. *J. Cancer Surviv.* **12**, 571–591 (2018).
213. Flocke, S. A. et al. Teachable moments for health behavior change and intermediate patient outcomes. *Patient Educ. Couns.* **96**, 43–49 (2014).
214. McDonald, S. et al. Exploring patient attitudes to behaviour change before surgery to reduce peri-operative risk: preferences for short- vs. long-term behaviour change. *Anaesthesia* **74**, 1580–1588 (2019).
215. Sallis, R. et al. Strategies for promoting physical activity in clinical practice. *Prog. Cardiovasc. Dis.* **57**, 375–386 (2015).
216. Gallagher, K. M. & Updegraff, J. A. Health message framing effects on attitudes, intentions, and behavior: a meta-analytic review. *Ann. Behav. Med.* **43**, 101–116 (2012).
217. Latimer, A. E. et al. Promoting participation in physical activity using framed messages: an application of prospect theory. *Br. J. Health Psychol.* **13**, 659–681 (2008).
218. Bandura, A. Health promotion by social cognitive means. *Health Educ. Behav.* **31**, 143–164 (2004).
219. Ajzen, I. The theory of planned behaviour: reactions and reflections. *Psychol. Health* **26**, 1113–1127 (2011).
220. Schutzer, K. A. & Graves, B. S. Barriers and motivations to exercise in older adults. *Prev. Med.* **39**, 1056–1061 (2004).
221. Champ, C. E., Francis, L., Klement, R. J., Dickerman, R. & Smith, R. P. Fortifying the treatment of prostate cancer with physical activity. *Prostate Cancer* **2016**, 9462975 (2016).
222. Low, C. A. et al. A real-time mobile intervention to reduce sedentary behavior before and after cancer surgery: usability and feasibility study. *JMIR Perioper. Med.* **5**, e17292 (2020).
223. Junwen, S. & Rongjiang, W. The efficacy of the WeChat app combined with pelvic floor muscle exercise for the urinary incontinence after radical prostatectomy. *Biomed. Res. Int.* **2020**, 6947839 (2020).
224. Hirschhorn, A. D., Kolt, G. S. & Brooks, A. J. A multicomponent theory-based intervention improves uptake of pelvic floor muscle training before radical prostatectomy: a ‘before and after’ cohort study. *BJU Int.* **113**, 383–392 (2014).
225. Hirschhorn, A. D., Kolt, G. S. & Brooks, A. J. Barriers and enablers to the provision and receipt of preoperative pelvic floor muscle training for men having radical prostatectomy: a qualitative study. *BMC Health Serv. Res.* **13**, 305 (2013).
226. Carli, F., Gillis, C. & Scheede-Bergdahl, C. Promoting a culture of prehabilitation for the surgical cancer patient. *Acta Oncol.* **56**, 128–133 (2017).
227. Patel, A., Schofield, G. & Keogh, J. Influences on health-care practitioners’ promotion of physical activity to their patients with prostate cancer: a qualitative study. *J. Prim. Health Care* **10**, 31–38 (2018).
228. Milios, J. E., Ackland, T. R. & Green, D. J. Pelvic floor muscle training in radical prostatectomy: a randomized controlled trial of the impacts on pelvic floor muscle function and urinary incontinence. *BMC Urol.* **19**, 116 (2019).
229. Aydin Sayilan, A. & Ozbas, A. The effect of pelvic floor muscle training on incontinence problems after radical prostatectomy. *Am. J. Mens. Health* **12**, 1007–1015 (2018).
230. Dijkstra-Eshuis, J. et al. Effect of preoperative pelvic floor muscle therapy with biofeedback versus standard care on stress urinary incontinence and quality of life in men undergoing laparoscopic radical prostatectomy: a randomised control trial. *NeuroUrol. Urodyn.* **34**, 144–150 (2015).
231. Ocampo-Trujillo, A. et al. Pre-operative training induces changes in the histomorphometry and muscle function of the pelvic floor in patients with indication of radical prostatectomy. *Actas Urol. Esp.* **38**, 378–384 (2014).
232. Geraerts, I. et al. Influence of preoperative and postoperative pelvic floor muscle training (PFMT) compared with postoperative PFMT on urinary incontinence after radical prostatectomy: a randomized controlled trial. *Eur. Urol.* **64**, 766–772 (2013).
233. Tienforti, D. et al. Efficacy of an assisted low-intensity programme of perioperative pelvic floor muscle training in improving the recovery of continence after radical prostatectomy: a randomized controlled trial. *BJU Int.* **110**, 1004–1010 (2012).
234. Dubbelman, Y., Groen, J., Wildhagen, M., Rikken, B. & Bosch, R. The recovery of urinary continence after radical retropubic prostatectomy: a randomized trial comparing the effect of physiotherapist-guided pelvic floor muscle exercises with guidance by an instruction folder only. *BJU Int.* **106**, 515–522 (2010).
235. Burgio, K. L. et al. Preoperative biofeedback assisted behavioral training to decrease post-prostatectomy incontinence: a randomized, controlled trial. *J. Urol.* **175**, 196–201; discussion 201 (2006).
236. Parekh, A. R. et al. The role of pelvic floor exercises on post-prostatectomy incontinence. *J. Urol.* **170**, 130–133 (2003).
237. Bales, G. T. et al. Effect of preoperative biofeedback/pelvic floor training on continence in men undergoing radical prostatectomy. *Urology* **56**, 627–630 (2000).
238. Küchler, H. Ueber Prostatavergrößerungen. *Dtsch. Klin.* **18**, 458–460 (1866).
239. Billroth, T. Carcinoma der prostata. *Chir. Erfahrungen, Zurich*, 1860–67. *Archiv Fur Klinische Chirurgie(Bd X)*, **10**, 548 (1869).
240. Millin, T. Retropubic prostatectomy: a new extravesical technique; report of 20 cases. *Lancet* **2**, 693–696 (1945).
241. Young, H. H. The cure of cancer of the prostate by radical perineal prostatectomy (prostato-seminal vesiculectomy): history, literature and statistics of Young’s operation. *J. Urol.* **53**, 188–252 (1945).

242. Chute, R. Radical retropubic prostatectomy for cancer. *J. Urol.* **71**, 347–372 (1954).
243. Ansell, J. S. Radical transvesical prostatectomy: preliminary report on an approach to surgical excision of localized prostatic malignancy. *J. Urol.* **82**, 373–374 (1959).
244. Campbell, E. W. Total prostatectomy with preliminary ligation of the vascular pedicles. *J. Urol.* **81**, 464–467 (1959).
245. McLaughlin, A. P., Saltzstein, S. L., McCullough, D. L. & Gittes, R. F. Prostatic carcinoma: incidence and location of unsuspected lymphatic metastases. *J. Urol.* **115**, 89–94 (1976).
246. Schuessler, W. W., Schulam, P. G., Clayman, R. V. & Kavoussi, L. R. Laparoscopic radical prostatectomy: initial short-term experience. *Urology* **50**, 854–857 (1997).
247. Guillonnet, B., Cathelineau, X., Barret, E., Rozet, F. & Vallancien, G. Laparoscopic radical prostatectomy. Preliminary evaluation after 28 interventions. *Presse Med.* **27**, 1570–1574 (1998).
248. Guillonnet, B. & Vallancien, G. Laparoscopic radical prostatectomy: the Montsouris experience. *J. Urol.* **163**, 418–422 (2000).
249. Binder, J. & Kramer, W. Robotically-assisted laparoscopic radical prostatectomy. *BJU Int.* **87**, 408–410 (2001).
250. Abbou, C. C. et al. Laparoscopic radical prostatectomy with a remote controlled robot. *J. Urol.* **165**, 1964–1966 (2001).
251. Abbou, C. C. et al. Remote laparoscopic radical prostatectomy carried out with a robot. Report of a case. *Prog. Urol.* **10**, 520–523 (2000).
252. Menon, M., Tewari, A., Baize, B., Guillonnet, B. & Vallancien, G. Prospective comparison of radical retropubic prostatectomy and robot-assisted anatomic prostatectomy: the Vattikuti Urology Institute experience. *Urology* **60**, 864–868 (2002).
253. Sotiropoulos, A., Yeaw, S. & Lattimer, J. K. Management of urinary incontinence with electronic stimulation: observations and results. *J. Urol.* **116**, 747–750 (1976).
254. Rudy, D. C., Woodside, J. R. & Crawford, E. D. Urodynamic evaluation of incontinence in patients undergoing modified Campbell radical retropubic prostatectomy: a prospective study. *J. Urol.* **132**, 708–712 (1984).
255. Opsomer, R., Castille, Y., Abi Aad, A. & van Cangh, P. Urinary incontinence after radical prostatectomy: is professional pelvic floor training necessary? *Neurourol. Urodyn.* **13**, 382–384 (1994).
256. Sueppel, C., Kreder, K. & See, W. Improved continence outcomes with preoperative pelvic floor muscle strengthening exercises. *Urol. Nurs.* **21**, 201–210 (2001).
257. Moore, K. N., Cody, D. J. & Glazener, C. M. Conservative management for post prostatectomy urinary incontinence. *Cochrane Database Syst. Rev.* **2**, CD001843 (2001).
258. Wang, W., Huang, Q. M., Liu, F. P. & Mao, Q. Q. Effectiveness of preoperative pelvic floor muscle training for urinary incontinence after radical prostatectomy: a meta-analysis. *BMC Urol.* **14**, 99 (2014).
259. Klotz, L. Active surveillance with selective delayed intervention: a biologically nuanced approach to favorable-risk prostate cancer. *Clin. Prostate Cancer* **2**, 106–110 (2003).

Acknowledgements

S.F.M. acknowledges support and assistance from The Clinical Research Institute, Ramsay Health Care and from philanthropic support from Charles Skowron and Kevin Sterns. S.V.C.'s work on this article was supported in part by funds from the Sidney Kimmel Center for Prostate and Urologic Cancers, a Specialized Programs of Research Excellence grant (P50-CA92629) from the National Cancer Institute to Dr. Howard Scher, a grant from the National Cancer Institute as part of the Cancer Intervention and Surveillance Modelling Network (U01-CA199338-02), the David H. Koch prostate cancer research fund, a National

Institutes of Health/National Cancer Institute Transition Career Development Award (K22-CA234400) and a grant from Memorial Sloan Kettering Cancer Center's Programs in Patient and Family Centred Care. S.V.C., J.S.S., O.A. and J.A.E. were supported in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant (P30-CA008748) to Memorial Sloan Kettering Cancer Center. The authors would like to sincerely thank Johanna Goldberg, librarian at Memorial Sloan Kettering Cancer Center, for her assistance with the literature search for this article.

Author contributions

S.F.M., S.V.C., G.C.G., P.L.G. and P.T.S. researched data for the article. All authors made substantial contributions to discussions of content. S.F.M., S.V.C., G.C.G., P.L.G., J.A.E. and M.I.P. wrote the manuscript. S.F.M., S.V.C., G.C.G., P.L.G., O.A., J.A.E. and M.I.P. reviewed and edited the manuscript before submission.

Competing interests

O.A. is an advisor to Ezra A.I. (unrelated to this Review). M.I.P. has received an honorarium from advisory board work for Astellas, Ferring, Janssen and AstraZeneca (unrelated to this Review). The other authors declare no competing interests.

Peer review information

Nature Reviews Urology thanks D. Kirages, C. Gozzi and L. Hall for their contribution to the peer review of this work.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

The online version contains supplementary material available at <https://doi.org/10.1038/s41585-021-00445-5>.

© Springer Nature Limited 2021